Section_Name,Content,Approved/Disapproved,Blanks,signature,final_response,Content_modified,Category,Entity Dictionary,Final_signature
Id,Prot Specific Site IC IC Main CA209-9DW USA 0195 13 May 2020 2.1 IEC-IRB Approved IC,,,,,,,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
MAIN INFORMED CONSENT AND RESEARCH AUTHORIZATION,"A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma",,,yes,yes,"A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma
I agree to the above statement",Certificate,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,We are inviting you to participate in this research study because you have been diagnosed with advanced liver cancer. Participation in this research study is voluntary. You may choose not to take part in this research study or may choose to leave the research study at any time. Your decision will not impact the clinical care you receive.,,,yes,yes,"We are inviting you to participate in this research study because you have been diagnosed with advanced liver cancer. Participation in this research study is voluntary. You may choose not to take part in this research study or may choose to leave the research study at any time. Your decision will not impact the clinical care you receive.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,"The purpose of this study is to test a combination treatment of study drugs called nivolumab and ipilimumab followed by nivolumab alone for your liver cancer. The researchers are studying how this combination works and how safe it is compared to the standard of care treatment (treatment that is usually used for your liver cancer), sorafenib or lenvatinib.",,,yes,yes,"The purpose of this study is to test a combination treatment of study drugs called nivolumab and ipilimumab followed by nivolumab alone for your liver cancer. The researchers are studying how this combination works and how safe it is compared to the standard of care treatment (treatment that is usually used for your liver cancer), sorafenib or lenvatinib.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Nivolumab and ipilimumab are types of immunotherapy that works by encouraging the body's own immune system to attack the cancer cells.,,,yes,yes,"Nivolumab and ipilimumab are types of immunotherapy that works by encouraging the body's own immune system to attack the cancer cells.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,"Participants in this study will need to sign this consent form before any testing or procedures can take place. This study is divided into 3 time periods: screening period, treatment period and a follow-up period. The screening period will determine if you meet the requirements to be part of the study. You will have laboratory work, review of your medical history and medication, tumor collection (if needed), tumor imaging and completing questionnaires during the screening period. The screening day visit will be approximately a 4-hour visit. All other visits will take approximately 1-2 hours.",,,yes,yes,"Participants in this study will need to sign this consent form before any testing or procedures can take place. This study is divided into 3 time periods: screening period, treatment period and a follow-up period. The screening period will determine if you meet the requirements to be part of the study. You will have laboratory work, review of your medical history and medication, tumor collection (if needed), tumor imaging and completing questionnaires during the screening period. The screening day visit will be approximately a 4-hour visit. All other visits will take approximately 1-2 hours.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,When you have met all the requirements you will enter the treatment period. This is where you will be randomly assigned (like a flip of a coin) to receive one of the following treatments:,,,yes,yes,"When you have met all the requirements you will enter the treatment period. This is where you will be randomly assigned (like a flip of a coin) to receive one of the following treatments:
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Investigational Therapy: Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg intravenously (IV; in a vein) on day 1 visit of each cycle every 3 weeks for up to 4 cycles. After 4 cycles you will receive nivolumab 480 mg alone every 4 weeks.,,,yes,yes,"Bullet- Investigational Therapy: Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg intravenously (IV; in a vein) on day 1 visit of each cycle every 3 weeks for up to 4 cycles. After 4 cycles you will receive nivolumab 480 mg alone every 4 weeks.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Standard of Care: Sorafenib 400 mg orally twice a day or lenvatinib 8 mg or 12 mg (depending on your body weight) orally once a day. Whether you receive sorafenib or lenvatinib will be based on the study doctorÃ¢ÂÂs judgment.,,,yes,yes,"Bullet- Standard of Care: Sorafenib 400 mg orally twice a day or lenvatinib 8 mg or 12 mg (depending on your body weight) orally once a day. Whether you receive sorafenib or lenvatinib will be based on the study doctorÃ¢ÂÂs judgment.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,During the treatment period you will have the following tests and procedures take place:,,,yes,yes,"During the treatment period you will have the following tests and procedures take place:
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Laboratory work,,,yes,yes,"Bullet- Laboratory work
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,"Site Version Date: March 24, 2020",,,yes,yes,"Site Version Date: March 24, 2020
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Sponsor Template Version and Date: Main ICF_USA_V2.1.0_24Jul2019,,,yes,yes,"Sponsor Template Version and Date: Main ICF_USA_V2.1.0_24Jul2019
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Page 1 of 41,,,yes,yes,"Page 1 of 41
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Physical exam,,,yes,yes,"Bullet- Physical exam
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,"Bullet- Vital signs (includes blood pressure, heart rate, temperature, respiratory rate)",,,yes,yes,"Bullet- Vital signs (includes blood pressure, heart rate, temperature, respiratory rate)
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Questionnaires,,,yes,yes,"Bullet- Questionnaires
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Review of medications,,,yes,yes,"Bullet- Review of medications
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Review of side effects,,,yes,yes,"Bullet- Review of side effects
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Tumor imaging (to check your tumor size or to see if the tumor has spread),,,yes,yes,"Bullet- Tumor imaging (to check your tumor size or to see if the tumor has spread)
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Electrocardiogram (ECG) Ã¢ÂÂ testing electrical activity of the heartbeat (required only if taking Lenvatinib),,,yes,yes,"Bullet- Electrocardiogram (ECG) Ã¢ÂÂ testing electrical activity of the heartbeat (required only if taking Lenvatinib)
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,There are risks to this study that are described in this document. Most common risks are included below with a complete list of risks provided in the Potential Risk section of this document.,,,yes,yes,"There are risks to this study that are described in this document. Most common risks are included below with a complete list of risks provided in the Potential Risk section of this document.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Most common risks with nivolumab combined with ipilimumab are:,,,yes,yes,"Bullet- Most common risks with nivolumab combined with ipilimumab are:
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- ALT and/or AST increased (lab test results associated with abnormal liver function),,,yes,yes,"Bullet- ALT and/or AST increased (lab test results associated with abnormal liver function)
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Diarrhea,,,yes,yes,"Bullet- Diarrhea
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Decreased appetite,,,yes,yes,"Bullet- Decreased appetite
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Fatigue,,,yes,yes,"Bullet- Fatigue
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Fever,,,yes,yes,"Bullet- Fever
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Itching,,,yes,yes,"Bullet- Itching
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Lipase increased (lab test result associated with pancreas inflammation),,,yes,yes,"Bullet- Lipase increased (lab test result associated with pancreas inflammation)
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Musculoskeletal pain,,,yes,yes,"Bullet- Musculoskeletal pain
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Nausea,,,yes,yes,"Bullet- Nausea
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Decreased thyroid function,,,yes,yes,"Bullet- Decreased thyroid function
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Rash,,,yes,yes,"Bullet- Rash
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Most common risks with nivolumab are:,,,yes,yes,"Bullet- Most common risks with nivolumab are:
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Diarrhea,,,yes,yes,"Bullet- Diarrhea
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Fatigue,,,yes,yes,"Bullet- Fatigue
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Itching,,,yes,yes,"Bullet- Itching
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Rash,,,yes,yes,"Bullet- Rash
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Lung inflammation (pneumonitis),,,yes,yes,"Bullet- Lung inflammation (pneumonitis)
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Most common risks with Sorafenib are:,,,yes,yes,"Bullet- Most common risks with Sorafenib are:
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Diarrhea,,,yes,yes,"Bullet- Diarrhea
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Feeling sick (nausea),,,yes,yes,"Bullet- Feeling sick (nausea)
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Feeling weak or tired (fatigue),,,yes,yes,"Bullet- Feeling weak or tired (fatigue)
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,"Bullet- Pain (including mouth pain, abdominal pain, headache, bone pain, tumor pain)",,,yes,yes,"Bullet- Pain (including mouth pain, abdominal pain, headache, bone pain, tumor pain)
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Hair loss (alopecia),,,yes,yes,"Bullet- Hair loss (alopecia)
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Flushed or painful palms or soles (hand foot skin reaction),,,yes,yes,"Bullet- Flushed or painful palms or soles (hand foot skin reaction)
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Itching or rash,,,yes,yes,"Bullet- Itching or rash
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Throwing up (vomiting),,,yes,yes,"Bullet- Throwing up (vomiting)
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,"Bullet- Bleeding (including bleeding in the brain, gut wall and respiratory tract (hemorrhage)",,,yes,yes,"Bullet- Bleeding (including bleeding in the brain, gut wall and respiratory tract (hemorrhage)
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,"Bullet- High blood pressure, or increases in blood pressure (hypertension)",,,yes,yes,"Bullet- High blood pressure, or increases in blood pressure (hypertension)
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Infections,,,yes,yes,"Bullet- Infections
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Loss of appetite (anorexia),,,yes,yes,"Bullet- Loss of appetite (anorexia)
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Constipation,,,yes,yes,"Bullet- Constipation
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Joint pain (arthralgia),,,yes,yes,"Bullet- Joint pain (arthralgia)
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Fever,,,yes,yes,"Bullet- Fever
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Weight loss,,,yes,yes,"Bullet- Weight loss
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Dry skin,,,yes,yes,"Bullet- Dry skin
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Most common risks with Lenvatinib are:,,,yes,yes,"Bullet- Most common risks with Lenvatinib are:
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- High or low blood pressure,,,yes,yes,"Bullet- High or low blood pressure
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Loss of appetite or weight loss,,,yes,yes,"Bullet- Loss of appetite or weight loss
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Feeling sick and being sick,,,yes,yes,"Bullet- Feeling sick and being sick
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Constipation,,,yes,yes,"Bullet- Constipation
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Diarrhea,,,yes,yes,"Bullet- Diarrhea
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Abdominal pain,,,yes,yes,"Bullet- Abdominal pain
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Indigestion,,,yes,yes,"Bullet- Indigestion
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Feeling very tired or weak,,,yes,yes,"Bullet- Feeling very tired or weak
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Hoarse voice,,,yes,yes,"Bullet- Hoarse voice
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Swelling of the legs,,,yes,yes,"Bullet- Swelling of the legs
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Rash,,,yes,yes,"Bullet- Rash
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,"Bullet- Dry, sore, or inflamed mouth",,,yes,yes,"Bullet- Dry, sore, or inflamed mouth
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Odd taste sensation,,,yes,yes,"Bullet- Odd taste sensation
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Joint or muscle pain,,,yes,yes,"Bullet- Joint or muscle pain
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Feeling dizzy,,,yes,yes,"Bullet- Feeling dizzy
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Hair loss,,,yes,yes,"Bullet- Hair loss
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,"Bullet- Bleeding (most commonly nose bleeds, but also other types of bleeding such as blood in the urine, bruising, bleeding from the gums or gut wall)",,,yes,yes,"Bullet- Bleeding (most commonly nose bleeds, but also other types of bleeding such as blood in the urine, bruising, bleeding from the gums or gut wall)
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Trouble sleeping,,,yes,yes,"Bullet- Trouble sleeping
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Changes in urine tests for protein (high) and urinary infections (increased frequency in urination and pain in passing urine),,,yes,yes,"Bullet- Changes in urine tests for protein (high) and urinary infections (increased frequency in urination and pain in passing urine)
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Headache and back pain,,,yes,yes,"Bullet- Headache and back pain
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,"Bullet- Redness, soreness and swelling of the skin on the hands and feet (hand-foot syndrome)",,,yes,yes,"Bullet- Redness, soreness and swelling of the skin on the hands and feet (hand-foot syndrome)
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,"Bullet- Underactive thyroid (tiredness, weight gain, constipation, feeling cold, dry skin)",,,yes,yes,"Bullet- Underactive thyroid (tiredness, weight gain, constipation, feeling cold, dry skin)
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Changes in blood test results for potassium levels (low) and calcium levels (low),,,yes,yes,"Bullet- Changes in blood test results for potassium levels (low) and calcium levels (low)
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Decrease in the number of white blood cells,,,yes,yes,"Bullet- Decrease in the number of white blood cells
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Changes in blood test results for liver function,,,yes,yes,"Bullet- Changes in blood test results for liver function
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,Bullet- Low levels of platelets in the blood which may lead to bruising and difficulty in wound healing.,,,yes,yes,"Bullet- Low levels of platelets in the blood which may lead to bruising and difficulty in wound healing.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Key Summary Information,"If you are interested in learning more about this study, please continue to read below.",,,yes,yes,"If you are interested in learning more about this study, please continue to read below.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Introduction and Background Information,You are invited to take part in a research study because you have been diagnosed with advanced liver cancer. The study is being conducted under the direction of Dr. Vivek Sharma at the University of Louisville. About 5 local subjects will be invited to take part in this research. The total number of subjects across all sites is estimated to be 650.,,,yes,yes,"You are invited to take part in a research study because you have been diagnosed with advanced liver cancer. The study is being conducted under the direction of Dr. Vivek Sharma at the University of Louisville. About 5 local subjects will be invited to take part in this research. The total number of subjects across all sites is estimated to be 650.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Introduction and Background Information,"Participating in a research study is not the same as getting regular medical care. The primary purpose of a research study is to collect information about a medical treatment; the purpose of regular medical care is to improve your health. Being in this study does not replace your regular medical care, but you may have additional evaluations or changes in your treatments during the study.",,,yes,yes,"Participating in a research study is not the same as getting regular medical care. The primary purpose of a research study is to collect information about a medical treatment; the purpose of regular medical care is to improve your health. Being in this study does not replace your regular medical care, but you may have additional evaluations or changes in your treatments during the study.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Introduction and Background Information,"Your participation in this study is voluntary. If you do not want to take part in the study, your decision will be respected. If you decide not to take part in this study, you can continue with your current medical care.",,,yes,yes,"Your participation in this study is voluntary. If you do not want to take part in the study, your decision will be respected. If you decide not to take part in this study, you can continue with your current medical care.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Introduction and Background Information,"Before participation in the study, you or your legally acceptable representative will receive a copy of the signed and dated written consent form and any other printed information that is provided.",,,yes,yes,"Before participation in the study, you or your legally acceptable representative will receive a copy of the signed and dated written consent form and any other printed information that is provided.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Purpose,"The purpose of this study is to see if there is improvement of your liver cancer (clinical benefit), to see if the study treatment is safe over a long period of time (long-term safety) and to collect information on your survival (survival data) with the investigational treatment (nivolumab with ipilimumab followed by nivolumab alone) in participants with advanced liver cancer who have not previously received a drug treatment for this disease. Nivolumab and ipilimumab are types of immunotherapy that work by encouraging the body's own immune system to attack the cancer cells. The main purpose of this study is to learn how well the investigational treatment works and how safe it is compared with other therapies that have already been approved by Food and Drug Administration (FDA) in this case, sorafenib or lenvatinib. Sorafenib and lenvatinib are standard of care treatments, which are treatments that are usually used first for your liver cancer.",,,yes,yes,"The purpose of this study is to see if there is improvement of your liver cancer (clinical benefit), to see if the study treatment is safe over a long period of time (long-term safety) and to collect information on your survival (survival data) with the investigational treatment (nivolumab with ipilimumab followed by nivolumab alone) in participants with advanced liver cancer who have not previously received a drug treatment for this disease. Nivolumab and ipilimumab are types of immunotherapy that work by encouraging the body's own immune system to attack the cancer cells. The main purpose of this study is to learn how well the investigational treatment works and how safe it is compared with other therapies that have already been approved by Food and Drug Administration (FDA) in this case, sorafenib or lenvatinib. Sorafenib and lenvatinib are standard of care treatments, which are treatments that are usually used first for your liver cancer.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Procedures,"Your participation in this study will last until your disease progresses or the side effects are not acceptable. If you consent to participate, you will have the following procedures while you are in this study. If you are assigned to receive nivolumab plus ipilimumab followed by nivolumab alone, you will stop receiving study treatment 2 years after you receive your first study treatment.",,,yes,yes,"Your participation in this study will last until your disease progresses or the side effects are not acceptable. If you consent to participate, you will have the following procedures while you are in this study. If you are assigned to receive nivolumab plus ipilimumab followed by nivolumab alone, you will stop receiving study treatment 2 years after you receive your first study treatment.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Procedures,"When you stop or complete study treatments, your study doctor will continue to assess your health condition. You will have follow-up visits approximately 30 days and 100 days after your last dose of study drug, and then study staff will follow up with you every 3 months until you leave the study or the study ends.",,,yes,yes,"When you stop or complete study treatments, your study doctor will continue to assess your health condition. You will have follow-up visits approximately 30 days and 100 days after your last dose of study drug, and then study staff will follow up with you every 3 months until you leave the study or the study ends.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Procedures,You will be randomly assigned (like the flip of a coin) to receive one of the following treatments:,,,yes,yes,"You will be randomly assigned (like the flip of a coin) to receive one of the following treatments:
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Procedures,Bullet- Investigational Therapy: Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg intravenous (IV; in a vein) on the day 1 visit of each cycle every 3 weeks for up to 4 cycles. After 4 cycles you will receive nivolumab 480 mg alone every 4 weeks.,,,yes,yes,"Bullet- Investigational Therapy: Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg intravenous (IV; in a vein) on the day 1 visit of each cycle every 3 weeks for up to 4 cycles. After 4 cycles you will receive nivolumab 480 mg alone every 4 weeks.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Procedures,Bullet- Standard of Care: Sorafenib 400 mg orally twice a day or lenvatinib 8 mg or 12 mg (depending on your body weight) orally once a day. Whether you receive sorafenib or lenvatinib will be based on the study doctorÃ¢ÂÂs judgment.,,,yes,yes,"Bullet- Standard of Care: Sorafenib 400 mg orally twice a day or lenvatinib 8 mg or 12 mg (depending on your body weight) orally once a day. Whether you receive sorafenib or lenvatinib will be based on the study doctorÃ¢ÂÂs judgment.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Procedures,You will have a 50% (1 in 2) chance of receiving nivolumab with ipilimumab followed by nivolumab alone and a 50% (1 in 2) chance of receiving the standard of care treatment: sorafenib or lenvatinib. You will be told which treatment that you are receiving.,,,yes,yes,"You will have a 50% (1 in 2) chance of receiving nivolumab with ipilimumab followed by nivolumab alone and a 50% (1 in 2) chance of receiving the standard of care treatment: sorafenib or lenvatinib. You will be told which treatment that you are receiving.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Procedures,"The study is divided into 3 time periods: a screening period, a treatment period, and a follow- up period. During each study period, you will have 1 or more visits with your study doctor at the center. The screening visit will last about 4 hours, but all other visits will last about 1 to 2 hours.",,,yes,yes,"The study is divided into 3 time periods: a screening period, a treatment period, and a follow- up period. During each study period, you will have 1 or more visits with your study doctor at the center. The screening visit will last about 4 hours, but all other visits will last about 1 to 2 hours.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Procedures,"A description of the procedures and assessments that will be performed during the study, including the screening, treatment, and follow-up visits, is shown in the table below. The study doctor will explain all the procedures and tests. In addition to the visits described below, the study doctor may ask you to come in for extra visits, if necessary, for your safety.",,,yes,yes,"A description of the procedures and assessments that will be performed during the study, including the screening, treatment, and follow-up visits, is shown in the table below. The study doctor will explain all the procedures and tests. In addition to the visits described below, the study doctor may ask you to come in for extra visits, if necessary, for your safety.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Procedures,The following tests and procedures will be performed by the study staff as part of this study:,,,yes,yes,"The following tests and procedures will be performed by the study staff as part of this study:
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Procedures,"Bullet- Collection of your urine and blood for laboratory tests to measure your blood chemistry, including kidney and liver function; how well your blood clots (coagulation parameters); red and white blood cells count and platelet counts; and measure your thyroid function. At screening, you will be also checked for hepatitis B, C, or D infection. You must not have knowledge of an active HIV infection or positive HIV test for you to participate in the study, and HIV testing may also be conducted if required by local law. You will be informed about these tests results. By Kentucky law we are to report the positive results of HIV and hepatitis B, C and D tests to the local Health Department nearest to where you live or to the Kentucky Department for Public Health.",,,yes,yes,"Bullet- Collection of your urine and blood for laboratory tests to measure your blood chemistry, including kidney and liver function; how well your blood clots (coagulation parameters); red and white blood cells count and platelet counts; and measure your thyroid function. At screening, you will be also checked for hepatitis B, C, or D infection. You must not have knowledge of an active HIV infection or positive HIV test for you to participate in the study, and HIV testing may also be conducted if required by local law. You will be informed about these tests results. By Kentucky law we are to report the positive results of HIV and hepatitis B, C and D tests to the local Health Department nearest to where you live or to the Kentucky Department for Public Health.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Procedures,Bullet- In addition to the samples above:,,,yes,yes,"Bullet- In addition to the samples above:
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Procedures,"Bullet- If you are positive for hepatitis B or C, additional blood samples will be collected during treatment and follow-up visits to monitor the disease status.",,,yes,yes,"Bullet- If you are positive for hepatitis B or C, additional blood samples will be collected during treatment and follow-up visits to monitor the disease status.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Procedures,"Bullet- If you are receiving nivolumab, alone or in combination with ipilimumab, additional blood samples will be drawn before and after some infusions to assess the levels of nivolumab and ipilimumab in your blood, as well as your immune response to nivolumab and/or ipilimumab.",,,yes,yes,"Bullet- If you are receiving nivolumab, alone or in combination with ipilimumab, additional blood samples will be drawn before and after some infusions to assess the levels of nivolumab and ipilimumab in your blood, as well as your immune response to nivolumab and/or ipilimumab.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Procedures,"Bullet- If you are receiving lenvatinib as standard of care, additional urine samples will be obtained during treatment and follow-up visits to monitor your renal function.",,,yes,yes,"Bullet- If you are receiving lenvatinib as standard of care, additional urine samples will be obtained during treatment and follow-up visits to monitor your renal function.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Procedures,"No more than 730 mL (about 3 cups) of total blood volume will be collected throughout the study, which includes about 10 mL (about a half a tablespoon) of blood collected at screening, about 500 mL (about 2 cups) during the treatment phase, and about 16 mL (about a tablespoon) at follow-up.",,,yes,yes,"No more than 730 mL (about 3 cups) of total blood volume will be collected throughout the study, which includes about 10 mL (about a half a tablespoon) of blood collected at screening, about 500 mL (about 2 cups) during the treatment phase, and about 16 mL (about a tablespoon) at follow-up.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Procedures,"Bullet- CT (computed topography) scan or magnetic resonance imaging (MRI) will be done to monitor the disease status. A CT is a test that uses a computer to make pictures of organs of the body. An MRI is a test that uses magnetic waves to look at soft tissues (connects, support or surrounds other structures and organs of the body i.e. muscles) of the body and create pictures. These pictures will allow your doctor to monitor your disease before, during, and after you receive study treatment to see if the tumors change in size or spread outside of the liver.",,,yes,yes,"Bullet- CT (computed topography) scan or magnetic resonance imaging (MRI) will be done to monitor the disease status. A CT is a test that uses a computer to make pictures of organs of the body. An MRI is a test that uses magnetic waves to look at soft tissues (connects, support or surrounds other structures and organs of the body i.e. muscles) of the body and create pictures. These pictures will allow your doctor to monitor your disease before, during, and after you receive study treatment to see if the tumors change in size or spread outside of the liver.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Procedures,Bullet- An ECG (or Ã¢ÂÂelectrocardiogramÃ¢ÂÂ) is a test that measures the electrical activity of the heart. A technician will place patches on your chest that will be connected by wires to a machine. An echocardiogram is used to take pictures of the structures and movements of the heart. A hand-held wand or patches are placed on your chest for the procedure.,,,yes,yes,"Bullet- An ECG (or Ã¢ÂÂelectrocardiogramÃ¢ÂÂ) is a test that measures the electrical activity of the heart. A technician will place patches on your chest that will be connected by wires to a machine. An echocardiogram is used to take pictures of the structures and movements of the heart. A hand-held wand or patches are placed on your chest for the procedure.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Procedures,"Bullet- If you have had a tumor biopsy/cancer surgery for your disease, your study doctor will request the original samples from the medical facility where it was done. If there is no tumor tissue available, you will be required to have a biopsy to obtain tumor tissue. To participate in this study, you must provide your permission to obtain tumor tissue samples and allow your study doctor to send them to an outside laboratory for investigational testing. Your study doctor may also request your permission to send additional tumor tissues samples if your disease progresses and if those samples are available, in a separate consent form. Your tumor samples will be tested to determine whether or not your cancer tumors have certain features that may help scientists better understand liver cancer and may also help scientists understand why your specific type of liver cancer tumor either responded or did not respond to the study drug. Scientists will look for certain types of genes and proteins that may be present on the surface of or within your tumor cells and may also look to see if certain types of white blood cells called lymphocytes are present within your tumors. Genomic (DNA/RNA) testing will be used to identify specific genetic variants related to cancer risk, prognosis, and treatments.",,,yes,yes,"Bullet- If you have had a tumor biopsy/cancer surgery for your disease, your study doctor will request the original samples from the medical facility where it was done. If there is no tumor tissue available, you will be required to have a biopsy to obtain tumor tissue. To participate in this study, you must provide your permission to obtain tumor tissue samples and allow your study doctor to send them to an outside laboratory for investigational testing. Your study doctor may also request your permission to send additional tumor tissues samples if your disease progresses and if those samples are available, in a separate consent form. Your tumor samples will be tested to determine whether or not your cancer tumors have certain features that may help scientists better understand liver cancer and may also help scientists understand why your specific type of liver cancer tumor either responded or did not respond to the study drug. Scientists will look for certain types of genes and proteins that may be present on the surface of or within your tumor cells and may also look to see if certain types of white blood cells called lymphocytes are present within your tumors. Genomic (DNA/RNA) testing will be used to identify specific genetic variants related to cancer risk, prognosis, and treatments.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Procedures,"Bullet- Measuring biomarkers (substances in your blood, stool, and tissue, such as proteins) could help predict whether or not someone is likely to benefit from a drug. Genomic (DNA/RNA) testing will be used to identify specific genetic variants that could show your",,,yes,yes,"Bullet- Measuring biomarkers (substances in your blood, stool, and tissue, such as proteins) could help predict whether or not someone is likely to benefit from a drug. Genomic (DNA/RNA) testing will be used to identify specific genetic variants that could show your
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Procedures,"cancer risk, how well your cancer might react to treatment, and which treatments might work best in your body. DNA is the material in a cell that carries all the information about how a living thing will look and function. This is known as genetic information.",,,yes,yes,"cancer risk, how well your cancer might react to treatment, and which treatments might work best in your body. DNA is the material in a cell that carries all the information about how a living thing will look and function. This is known as genetic information.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Procedures,"Genes are sections of the DNA that carry pieces of information. In addition to DNA, another part of the cell, RNA, helps to make proteins and can also carry genetic information. This study has testing that may reveal the genetic information carried by your DNA and RNA. During the course of this study, researchers may run biomarker tests on your samples to answer the questions being asked in this study. Biomarkers include proteins, DNA, RNA, and other molecules which can be found in blood, other body fluids, or tissues. Biomarker tests can aid in understanding how or if a body will respond to a treatment and predicting how a disease will progress. The information from these tests may also be used to create or improve tests that may help predict how study participants and their disease will respond to treatment or to help choose the right drug for each study participant.",,,yes,yes,"Genes are sections of the DNA that carry pieces of information. In addition to DNA, another part of the cell, RNA, helps to make proteins and can also carry genetic information. This study has testing that may reveal the genetic information carried by your DNA and RNA. During the course of this study, researchers may run biomarker tests on your samples to answer the questions being asked in this study. Biomarkers include proteins, DNA, RNA, and other molecules which can be found in blood, other body fluids, or tissues. Biomarker tests can aid in understanding how or if a body will respond to a treatment and predicting how a disease will progress. The information from these tests may also be used to create or improve tests that may help predict how study participants and their disease will respond to treatment or to help choose the right drug for each study participant.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Procedures,"The samples collected for biomarker testing during this study will be used for the purposes described in the study procedures section and will be destroyed at the end of their usable life or the end of the scheduled storage period, whichever comes first. The scheduled storage period begins 2 years after the final study report is written and will be for 15 years or the maximum allowed by applicable law.",,,yes,yes,"The samples collected for biomarker testing during this study will be used for the purposes described in the study procedures section and will be destroyed at the end of their usable life or the end of the scheduled storage period, whichever comes first. The scheduled storage period begins 2 years after the final study report is written and will be for 15 years or the maximum allowed by applicable law.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Procedures,"The biomarker testing described in this section is required for the main study. This is separate from the use of samples for additional research, which is described later in this consent.",,,yes,yes,"The biomarker testing described in this section is required for the main study. This is separate from the use of samples for additional research, which is described later in this consent.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Procedures,"All information collected, as described above, will be kept confidential. For details, see the Confidentiality section of this informed consent.",,,yes,yes,"All information collected, as described above, will be kept confidential. For details, see the Confidentiality section of this informed consent.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Procedures,Abbreviations: ECG = electrocardiogram; CT = computed topography; MRI = magnetic resonance imaging.,,,yes,yes,"Abbreviations: ECG = electrocardiogram; CT = computed topography; MRI = magnetic resonance imaging.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Procedures,"After the Day 100 (ÃÂ±7 days) Follow-Up Visit, you will have subsequent Follow-Up Visits every 3 months until you leave the study or the study ends. Those Follow-Up Visits may be done by telephone call. Your survival status will be recorded, and you will be asked about any additional cancer therapies you received after the study treatment was stopped and asked to answer survey questions about your health and activities you are able to perform.",,,yes,yes,"After the Day 100 (ÃÂ±7 days) Follow-Up Visit, you will have subsequent Follow-Up Visits every 3 months until you leave the study or the study ends. Those Follow-Up Visits may be done by telephone call. Your survival status will be recorded, and you will be asked about any additional cancer therapies you received after the study treatment was stopped and asked to answer survey questions about your health and activities you are able to perform.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Procedures,"In the event it is necessary to further evaluate the safety or efficacy of the drug, it may be necessary to have access to additional information about your health status. Your study doctor may attempt to obtain study-related information about your health from you or from other sources, including your primary care physician and public sources such as national patient registries (eg, cancer registries). This may include contacting you again by phone or letter. If your study doctor needs to follow up with you but cannot find you, he may try to learn your new address, telephone number, or current health status by calling or writing to the person(s) named as your secondary contact(s). If your study doctor cannot obtain information through your secondary contact(s), he or she may ask for the assistance of a third-party representative and may share with that representative limited information about you, such as your name and last known address. The representative will consult public sources, such as public health registries and databases, to obtain your current contact information. The representative will only share this information with the study doctor, to help him complete the follow-up stage of the trial. No one but the study doctor or a member of his team will contact you or your family members.",,,yes,yes,"In the event it is necessary to further evaluate the safety or efficacy of the drug, it may be necessary to have access to additional information about your health status. Your study doctor may attempt to obtain study-related information about your health from you or from other sources, including your primary care physician and public sources such as national patient registries (eg, cancer registries). This may include contacting you again by phone or letter. If your study doctor needs to follow up with you but cannot find you, he may try to learn your new address, telephone number, or current health status by calling or writing to the person(s) named as your secondary contact(s). If your study doctor cannot obtain information through your secondary contact(s), he or she may ask for the assistance of a third-party representative and may share with that representative limited information about you, such as your name and last known address. The representative will consult public sources, such as public health registries and databases, to obtain your current contact information. The representative will only share this information with the study doctor, to help him complete the follow-up stage of the trial. No one but the study doctor or a member of his team will contact you or your family members.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
What do I have to do?,Bullet- Tell your study doctor,,,yes,yes,"Bullet- Tell your study doctor
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
What do I have to do?,"Bullet- if you have any allergies, including drug allergies; if you are unsure, ask your primary doctor.",,,yes,yes,"Bullet- if you have any allergies, including drug allergies; if you are unsure, ask your primary doctor.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
What do I have to do?,"Bullet- of any changes to your current medications, illnesses or injuries, unexpected or troublesome side effects, or problems that occur during the study.",,,yes,yes,"Bullet- of any changes to your current medications, illnesses or injuries, unexpected or troublesome side effects, or problems that occur during the study.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
What do I have to do?,Bullet- if you plan to have an elective surgery or any other medical treatment or procedure.,,,yes,yes,"Bullet- if you plan to have an elective surgery or any other medical treatment or procedure.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
What do I have to do?,Bullet- if you plan to start taking any medication (prescription or over the counter).,,,yes,yes,"Bullet- if you plan to start taking any medication (prescription or over the counter).
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
What do I have to do?,Bullet- if you find you have any questions about the study after you sign this form.,,,yes,yes,"Bullet- if you find you have any questions about the study after you sign this form.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
What do I have to do?,Bullet- Attend all scheduled visits.,,,yes,yes,"Bullet- Attend all scheduled visits.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
What do I have to do?,Bullet- Follow the study doctorÃ¢ÂÂs instructions about whether or not you may continue to take your regular prescribed medications or over-the-counter medicines or herbal,,,yes,yes,"Bullet- Follow the study doctorÃ¢ÂÂs instructions about whether or not you may continue to take your regular prescribed medications or over-the-counter medicines or herbal
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
What do I have to do?,"supplements during the study period. Certain medications cannot be taken while you are participating in this trial. This includes certain vaccines. Your study doctor will explain what these medications are. If you need treatment with any medications that are not allowed during your participation in this trial, you must inform the study doctor or the study staff. You will not be denied medications required to treat an illness you may have, but you may be required to stop taking the study medication. This is for your safety, since some medications may not work well with the study treatment, and you might have physical problems.",,,yes,yes,"supplements during the study period. Certain medications cannot be taken while you are participating in this trial. This includes certain vaccines. Your study doctor will explain what these medications are. If you need treatment with any medications that are not allowed during your participation in this trial, you must inform the study doctor or the study staff. You will not be denied medications required to treat an illness you may have, but you may be required to stop taking the study medication. This is for your safety, since some medications may not work well with the study treatment, and you might have physical problems.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
What do I have to do?,Bullet- You should continue to make regular visits to your primary doctor or any other special doctors you were seeing before starting the study because being in the study does not replace regular medical care.,,,yes,yes,"Bullet- You should continue to make regular visits to your primary doctor or any other special doctors you were seeing before starting the study because being in the study does not replace regular medical care.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
What do I have to do?,"Bullet- You and/or your partner must use a reliable form of contraception during the study (as described in this form). If you or your partner becomes pregnant while you are in the study, be sure to tell the study doctor as soon as possible.",,,yes,yes,"Bullet- You and/or your partner must use a reliable form of contraception during the study (as described in this form). If you or your partner becomes pregnant while you are in the study, be sure to tell the study doctor as soon as possible.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
What do I have to do?,Bullet- Provide alternative contact details to keep the study doctor up to date during the study (to avoid loss to follow up) for survival data.,,,yes,yes,"Bullet- Provide alternative contact details to keep the study doctor up to date during the study (to avoid loss to follow up) for survival data.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
What do I have to do?,Bullet- Provide follow-up data as requested even after treatment has stopped.,,,yes,yes,"Bullet- Provide follow-up data as requested even after treatment has stopped.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
What do I have to do?,Bullet- Participants receiving sorafenib or lenvatinib must return any unused bottles and capsules at each site visit.,,,yes,yes,"Bullet- Participants receiving sorafenib or lenvatinib must return any unused bottles and capsules at each site visit.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
What do I have to do?,"Bullet- If you are provided with a Subject Alert Card, please carry it with you at all times.",,,yes,yes,"Bullet- If you are provided with a Subject Alert Card, please carry it with you at all times.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
What do I have to do?,The use of your samples may result in commercial profit. You will no longer have any ownership in the samples. You will not be compensated for the use of your samples other than what is described in this consent form nor will you be able to have the samples returned to you.,,,yes,yes,"The use of your samples may result in commercial profit. You will no longer have any ownership in the samples. You will not be compensated for the use of your samples other than what is described in this consent form nor will you be able to have the samples returned to you.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
What do I have to do?,"Your samples will be stored and shared for future research without additional informed consent if identifiable private information, such as your name and medical record number, are removed. If identifying information is removed from your samples, the samples may be used for future research studies or given to another investigator for future research studies without additional consent from you.",,,yes,yes,"Your samples will be stored and shared for future research without additional informed consent if identifiable private information, such as your name and medical record number, are removed. If identifying information is removed from your samples, the samples may be used for future research studies or given to another investigator for future research studies without additional consent from you.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Potential Risks,"Treatments for cancer often have side effects, including some that are life-threatening or fatal. There is the possibility that death will occur as a result of study treatments and its side effects. There may be additional unknown risks.",,,yes,yes,"Treatments for cancer often have side effects, including some that are life-threatening or fatal. There is the possibility that death will occur as a result of study treatments and its side effects. There may be additional unknown risks.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Potential Risks,"If you experience severe side effects associated with the study drugs, your doctor may prescribe medications to treat the side effect(s), future treatments may be delayed or",,,yes,yes,"If you experience severe side effects associated with the study drugs, your doctor may prescribe medications to treat the side effect(s), future treatments may be delayed or
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Potential Risks,"interrupted, or treatment may be stopped permanently. Any significant new findings that develop during the course of the research and may relate to your willingness to continue participation will be provided to you. You should tell your doctor or nurse right away about any possible side effects you experience.",,,yes,yes,"interrupted, or treatment may be stopped permanently. Any significant new findings that develop during the course of the research and may relate to your willingness to continue participation will be provided to you. You should tell your doctor or nurse right away about any possible side effects you experience.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Potential Risks,Based on what we have learned up to this point about study drugs the following drug reactions are known:,,,yes,yes,"Based on what we have learned up to this point about study drugs the following drug reactions are known:
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Potential Risks,Nivolumab combined with ipilimumab,,,yes,yes,"Nivolumab combined with ipilimumab
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Potential Risks,"Nivolumab with ipilimumab may cause one or more of the side effects listed below. This information is based on data from cancer patients in other clinical trials with nivolumab and ipilimumab. In addition, there may be side effects that are not yet known that may occur.",,,yes,yes,"Nivolumab with ipilimumab may cause one or more of the side effects listed below. This information is based on data from cancer patients in other clinical trials with nivolumab and ipilimumab. In addition, there may be side effects that are not yet known that may occur.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Potential Risks,The following table details the known risks related to this research and how often they may occur.,,,yes,yes,"The following table details the known risks related to this research and how often they may occur.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Potential Risks,Nivolumab alone,,,yes,yes,"Nivolumab alone
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Potential Risks,"If during the study, you receive nivolumab monotherapy, the doctor will discuss the side effects with you. The toxicities are similar to those listed above for nivolumab in combination with ipilimumab; however, how likely they are to occur (whether they are common or rare) may be slightly different than for nivolumab given in combination with ipilimumab. For example, very common side effects of nivolumab alone are diarrhea, fatigue, itching and rash.",,,yes,yes,"If during the study, you receive nivolumab monotherapy, the doctor will discuss the side effects with you. The toxicities are similar to those listed above for nivolumab in combination with ipilimumab; however, how likely they are to occur (whether they are common or rare) may be slightly different than for nivolumab given in combination with ipilimumab. For example, very common side effects of nivolumab alone are diarrhea, fatigue, itching and rash.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Potential Risks,"Lung Inflammation (pneumonitis): It is possible that nivolumab (alone or in combination with ipilimumab) may cause inflammation of the tissues of the lung. This side effect has been reported in patients treated with nivolumab. While many patients with x-ray or computed topography (CT) abnormalities have not developed any symptoms, some patients have developed mild-to-severe symptoms and, in rare cases, death has occurred as a result of their lung inflammation. Signs and symptoms of lung inflammation may include difficulty breathing, pain or discomfort while breathing, chest pain, cough, shortness of breath, increased rate of breathing, fever, low blood oxygen levels, or fatigue.",,,yes,yes,"Lung Inflammation (pneumonitis): It is possible that nivolumab (alone or in combination with ipilimumab) may cause inflammation of the tissues of the lung. This side effect has been reported in patients treated with nivolumab. While many patients with x-ray or computed topography (CT) abnormalities have not developed any symptoms, some patients have developed mild-to-severe symptoms and, in rare cases, death has occurred as a result of their lung inflammation. Signs and symptoms of lung inflammation may include difficulty breathing, pain or discomfort while breathing, chest pain, cough, shortness of breath, increased rate of breathing, fever, low blood oxygen levels, or fatigue.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Potential Risks,"Your study doctor and nurse will watch you closely for changes in your ability to breathe and for other signs or symptoms that might show you are developing this type of lung inflammation, and they will perform regular tests including physical examinations, measurement of oxygen levels through non-invasive testing (ie, pulse oximeter), blood tests, chest x-rays, and/or CT scans.",,,yes,yes,"Your study doctor and nurse will watch you closely for changes in your ability to breathe and for other signs or symptoms that might show you are developing this type of lung inflammation, and they will perform regular tests including physical examinations, measurement of oxygen levels through non-invasive testing (ie, pulse oximeter), blood tests, chest x-rays, and/or CT scans.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Please inform your study doctor or nurse AT ONCE if you experience any of the following:,Bullet- any new or increased shortness of breath,,,yes,yes,"Bullet- any new or increased shortness of breath
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Please inform your study doctor or nurse AT ONCE if you experience any of the following:,Bullet- any new or increased chest pain,,,yes,yes,"Bullet- any new or increased chest pain
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Please inform your study doctor or nurse AT ONCE if you experience any of the following:,Bullet- any new or increased pain/difficulty while breathing,,,yes,yes,"Bullet- any new or increased pain/difficulty while breathing
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Please inform your study doctor or nurse AT ONCE if you experience any of the following:,Bullet- any new or increased cough or any significant change in your type of cough; for example any new or increased mucous or blood in your cough,,,yes,yes,"Bullet- any new or increased cough or any significant change in your type of cough; for example any new or increased mucous or blood in your cough
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Please inform your study doctor or nurse AT ONCE if you experience any of the following:,Bullet- any change in the amount of oxygen you require,,,yes,yes,"Bullet- any change in the amount of oxygen you require
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Please inform your study doctor or nurse AT ONCE if you experience any of the following:,"Bullet- any fever, fatigue, or other symptoms that occur at the same time as any changes to your breathing or other lung symptoms",,,yes,yes,"Bullet- any fever, fatigue, or other symptoms that occur at the same time as any changes to your breathing or other lung symptoms
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Please inform your study doctor or nurse AT ONCE if you experience any of the following:,"If you start to feel these symptoms, your study doctor will ask you to return to the clinic for additional tests, which could include a physical examination, measurement of oxygen levels, blood tests, chest x-rays, and/or CT scans. You will be monitored very closely for changes in your overall lung symptoms; monitoring may require hospitalization. You may require specific treatment to control pneumonitis. You may also be seen by a special doctor, called a pulmonologist, who has special training to be an expert in how your lungs work.",,,yes,yes,"If you start to feel these symptoms, your study doctor will ask you to return to the clinic for additional tests, which could include a physical examination, measurement of oxygen levels, blood tests, chest x-rays, and/or CT scans. You will be monitored very closely for changes in your overall lung symptoms; monitoring may require hospitalization. You may require specific treatment to control pneumonitis. You may also be seen by a special doctor, called a pulmonologist, who has special training to be an expert in how your lungs work.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Other side effects for nivolumab with or without ipilimumab:,"Bullet- Prolonged treatment with medicines that reduce inflammation, sometimes needed to manage the side effects of nivolumab with or without ipilimumab treatment, may lower your",,,yes,yes,"Bullet- Prolonged treatment with medicines that reduce inflammation, sometimes needed to manage the side effects of nivolumab with or without ipilimumab treatment, may lower your
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Other side effects for nivolumab with or without ipilimumab:,"bodyÃ¢ÂÂs ability to fight off certain infections (ie, opportunistic infections). These infections may require treatment with antibiotic or antifungal medications and may be fatal.",,,yes,yes,"bodyÃ¢ÂÂs ability to fight off certain infections (ie, opportunistic infections). These infections may require treatment with antibiotic or antifungal medications and may be fatal.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Other side effects for nivolumab with or without ipilimumab:,"Bullet- Complications, including fatal events, have occurred in patients who received allogeneic hematopoietic stem cell transplantation (HSCT) before or after nivolumab.",,,yes,yes,"Bullet- Complications, including fatal events, have occurred in patients who received allogeneic hematopoietic stem cell transplantation (HSCT) before or after nivolumab.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Other side effects for nivolumab with or without ipilimumab:,"Bullet- Complications, including rejection, have also been reported in patients who have received an organ or tissue transplant. Treatment with nivolumab may increase the risk of rejection of the organ or tissue transplant.",,,yes,yes,"Bullet- Complications, including rejection, have also been reported in patients who have received an organ or tissue transplant. Treatment with nivolumab may increase the risk of rejection of the organ or tissue transplant.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Other side effects for nivolumab with or without ipilimumab:,Sorafenib,,,yes,yes,"Sorafenib
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Other side effects for nivolumab with or without ipilimumab:,"Sorafenib may cause one or more of the side effects listed below. This information is based on data from the Sorafenib Patient Leaflet (June 2018). In addition, there may be side effects that are not yet known that may occur.",,,yes,yes,"Sorafenib may cause one or more of the side effects listed below. This information is based on data from the Sorafenib Patient Leaflet (June 2018). In addition, there may be side effects that are not yet known that may occur.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Other side effects for nivolumab with or without ipilimumab:,Lenvatinib,,,yes,yes,"Lenvatinib
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Other side effects for nivolumab with or without ipilimumab:,"Lenvatinib may cause one or more of the side effects listed below. This information is based on data from the Lenvatinib Patient Leaflet (February 2019). In addition, there may be side effects that are not yet known that may occur.",,,yes,yes,"Lenvatinib may cause one or more of the side effects listed below. This information is based on data from the Lenvatinib Patient Leaflet (February 2019). In addition, there may be side effects that are not yet known that may occur.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Other side effects for nivolumab with or without ipilimumab:,Other side effects (regardless of study treatment),,,yes,yes,"Other side effects (regardless of study treatment)
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Other side effects for nivolumab with or without ipilimumab:,Regardless which study treatment you receive you may experience other side effects associated to study procedures:,,,yes,yes,"Regardless which study treatment you receive you may experience other side effects associated to study procedures:
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Other side effects for nivolumab with or without ipilimumab:,"Bullet- Side effects associated with blood draws or use of an IV catheter may include infection, bruising, redness, discomfort, or bleeding at the needle puncture site.",,,yes,yes,"Bullet- Side effects associated with blood draws or use of an IV catheter may include infection, bruising, redness, discomfort, or bleeding at the needle puncture site.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Other side effects for nivolumab with or without ipilimumab:,"Bullet- Sometimes study participants have allergic reactions to the dyes used in CT scans. This is rare and can involve itching or rash. In severe cases, you may have difficulty breathing and dangerous lowering of your blood pressure. If you know you have an allergy to the dye, or to iodine or shellfish, please let your study doctor and radiologist know. These scans are also associated with exposure to varying amounts of radiation.",,,yes,yes,"Bullet- Sometimes study participants have allergic reactions to the dyes used in CT scans. This is rare and can involve itching or rash. In severe cases, you may have difficulty breathing and dangerous lowering of your blood pressure. If you know you have an allergy to the dye, or to iodine or shellfish, please let your study doctor and radiologist know. These scans are also associated with exposure to varying amounts of radiation.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Other side effects for nivolumab with or without ipilimumab:,"Bullet- A liver biopsy may cause pain and bruising at the biopsy or incision site and may cause other complications such as tumor seeding or bleeding, which may require hospitalization, transfusions, and sometimes surgery or another procedure to stop the bleeding.",,,yes,yes,"Bullet- A liver biopsy may cause pain and bruising at the biopsy or incision site and may cause other complications such as tumor seeding or bleeding, which may require hospitalization, transfusions, and sometimes surgery or another procedure to stop the bleeding.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Other side effects for nivolumab with or without ipilimumab:,There may be risks or side effects which are unknown at this time.,,,yes,yes,"There may be risks or side effects which are unknown at this time.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Other side effects for nivolumab with or without ipilimumab:,Your condition may not get better or may become worse while you are in this study.,,,yes,yes,"Your condition may not get better or may become worse while you are in this study.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Other side effects for nivolumab with or without ipilimumab:,Certain drugs may increase the severity of these side effects if taken during the study. Ask your study doctor for a full list of prohibited medications.,,,yes,yes,"Certain drugs may increase the severity of these side effects if taken during the study. Ask your study doctor for a full list of prohibited medications.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Possible Pregnancy Risks,"Nivolumab, the combination of nivolumab and ipilimumab, sorafenib and lenvatinib have been studied in laboratory and animal experiments to see if they cause problems with pregnancy or birth defects. Their use in pregnant women has not been formally studied in clinical studies.",,,yes,yes,"Nivolumab, the combination of nivolumab and ipilimumab, sorafenib and lenvatinib have been studied in laboratory and animal experiments to see if they cause problems with pregnancy or birth defects. Their use in pregnant women has not been formally studied in clinical studies.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Possible Pregnancy Risks,"There is not enough information to determine if they could cause problems for a pregnancy or developing baby, and therefore it is not possible to say that nothing bad will happen when a woman gets pregnant while she or her sexual partner is taking these drugs. Because many medicinal products, including antibodies, can be secreted in human milk, a risk to newborns/infants cannot be excluded. Taking the study drug may involve unknown risks to a pregnant woman, an embryo, fetus (unborn baby), or nursing infant. Therefore, if you are a woman who is pregnant, planning to become pregnant, or are breastfeeding a child, you cannot take part in this study.",,,yes,yes,"There is not enough information to determine if they could cause problems for a pregnancy or developing baby, and therefore it is not possible to say that nothing bad will happen when a woman gets pregnant while she or her sexual partner is taking these drugs. Because many medicinal products, including antibodies, can be secreted in human milk, a risk to newborns/infants cannot be excluded. Taking the study drug may involve unknown risks to a pregnant woman, an embryo, fetus (unborn baby), or nursing infant. Therefore, if you are a woman who is pregnant, planning to become pregnant, or are breastfeeding a child, you cannot take part in this study.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Possible Pregnancy Risks,"If you (or your partner) become pregnant while in this study, the sponsor may ask to follow the outcome of the pregnancy. If you agree to allow the study doctor to follow your pregnancy,",,,yes,yes,"If you (or your partner) become pregnant while in this study, the sponsor may ask to follow the outcome of the pregnancy. If you agree to allow the study doctor to follow your pregnancy,
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Possible Pregnancy Risks,you will be asked to read and sign a separate consent form for permission to follow the outcome of your pregnancy.,,,yes,yes,"you will be asked to read and sign a separate consent form for permission to follow the outcome of your pregnancy.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Possible Pregnancy Risks,"While you are taking the study treatments, you must not be pregnant or breastfeeding, and you should not become pregnant or breastfeed while receiving the study treatment and for up to 5 months (if you receive nivolumab plus ipilimumab followed by nivolumab alone), 40 days (if you receive sorafenib), or 36 days (if you receive lenvatinib) after the last dose of study treatment. During that period you must use a highly effective method of birth control to prevent pregnancy. Highly effective birth control methods include:",,,yes,yes,"While you are taking the study treatments, you must not be pregnant or breastfeeding, and you should not become pregnant or breastfeed while receiving the study treatment and for up to 5 months (if you receive nivolumab plus ipilimumab followed by nivolumab alone), 40 days (if you receive sorafenib), or 36 days (if you receive lenvatinib) after the last dose of study treatment. During that period you must use a highly effective method of birth control to prevent pregnancy. Highly effective birth control methods include:
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Possible Pregnancy Risks,"Bullet- oral, intravaginal, or transdermal combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation",,,yes,yes,"Bullet- oral, intravaginal, or transdermal combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Possible Pregnancy Risks,"Bullet- oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation",,,yes,yes,"Bullet- oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Possible Pregnancy Risks,"Bullet- hormonal methods of contraception including oral contraceptive pills containing a combination of estrogen and progesterone, vaginal ring, injectables, implants and intrauterine hormone-releasing system",,,yes,yes,"Bullet- hormonal methods of contraception including oral contraceptive pills containing a combination of estrogen and progesterone, vaginal ring, injectables, implants and intrauterine hormone-releasing system
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Possible Pregnancy Risks,Bullet- intrauterine device,,,yes,yes,"Bullet- intrauterine device
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Possible Pregnancy Risks,Bullet- bilateral tubal occlusion,,,yes,yes,"Bullet- bilateral tubal occlusion
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Possible Pregnancy Risks,Bullet- complete abstinence,,,yes,yes,"Bullet- complete abstinence
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Possible Pregnancy Risks,"If you are a man taking part in the study and your partner becomes pregnant, the study doctor may ask you to ask your partner for permission to follow her pregnancy. If she agrees, she will be asked to sign a separate consent form mentioned above.",,,yes,yes,"If you are a man taking part in the study and your partner becomes pregnant, the study doctor may ask you to ask your partner for permission to follow her pregnancy. If she agrees, she will be asked to sign a separate consent form mentioned above.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Possible Pregnancy Risks,"Male participants with female partners of childbearing potential must be surgically sterile or compliant with a highly effective birth control method. In addition, men must agree to the following for the duration of study treatment and for up 7 months (if you receive nivolumab plus ipilimumab followed by nivolumab alone), 100 days (if you receive sorafenib), or 96 days (if you receive lenvatinib) after the last dose of study treatment:",,,yes,yes,"Male participants with female partners of childbearing potential must be surgically sterile or compliant with a highly effective birth control method. In addition, men must agree to the following for the duration of study treatment and for up 7 months (if you receive nivolumab plus ipilimumab followed by nivolumab alone), 100 days (if you receive sorafenib), or 96 days (if you receive lenvatinib) after the last dose of study treatment:
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Possible Pregnancy Risks,Bullet- You must not father a child,,,yes,yes,"Bullet- You must not father a child
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Possible Pregnancy Risks,Bullet- Use a condom.,,,yes,yes,"Bullet- Use a condom.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Possible Pregnancy Risks,"Bullet- Inform any and all partners that you are participating in a clinical drug study, and your partner must use highly effective birth control (described above).",,,yes,yes,"Bullet- Inform any and all partners that you are participating in a clinical drug study, and your partner must use highly effective birth control (described above).
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Possible Pregnancy Risks,Bullet- Refrain from donating sperm.,,,yes,yes,"Bullet- Refrain from donating sperm.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Possible Pregnancy Risks,"Bullet- Tell the study doctor if your partner becomes pregnant during the clinical trial. While your sexual partner is pregnant or breastfeeding, you must agree to remain abstinent from penile vaginal intercourse or use a male condom during each episode of penile penetration. You and your partner will be asked to provide information about the pregnancy outcome.",,,yes,yes,"Bullet- Tell the study doctor if your partner becomes pregnant during the clinical trial. While your sexual partner is pregnant or breastfeeding, you must agree to remain abstinent from penile vaginal intercourse or use a male condom during each episode of penile penetration. You and your partner will be asked to provide information about the pregnancy outcome.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Possible Pregnancy Risks,"Before starting this research study, females able to have children will have a pregnancy test. Talk to your doctor about the best method of birth control to use while you are in this study. It is important that you call your study doctor at (502) 562-4370 right away if you become",,,yes,yes,"Before starting this research study, females able to have children will have a pregnancy test. Talk to your doctor about the best method of birth control to use while you are in this study. It is important that you call your study doctor at (502) 562-4370 right away if you become
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Possible Pregnancy Risks,"pregnant or father a child during the course of this study. If you or your partner becomes pregnant, a decision may have to be made whether or not to end the pregnancy.",,,yes,yes,"pregnant or father a child during the course of this study. If you or your partner becomes pregnant, a decision may have to be made whether or not to end the pregnancy.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Possible Pregnancy Risks,"We do not know the effects of nivolumab, the combination of nivolumab and ipilimumab, sorafenib and lenvatinib on an unborn baby. There is a risk that your unborn baby could be harmed if you become pregnant during your participation in the study. (If you ask, your study doctor will discuss the possible risks to your unborn child and your options should you become pregnant while in this study.)",,,yes,yes,"We do not know the effects of nivolumab, the combination of nivolumab and ipilimumab, sorafenib and lenvatinib on an unborn baby. There is a risk that your unborn baby could be harmed if you become pregnant during your participation in the study. (If you ask, your study doctor will discuss the possible risks to your unborn child and your options should you become pregnant while in this study.)
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Research Involving Genetic Information,"A Federal law, called the Genetic Information Nondiscrimination Act (GINA), generally makes it illegal for health insurance companies, group health plans, and most employers to discriminate against you based on your genetic information. This law generally will protect you in the following ways:",,,yes,yes,"A Federal law, called the Genetic Information Nondiscrimination Act (GINA), generally makes it illegal for health insurance companies, group health plans, and most employers to discriminate against you based on your genetic information. This law generally will protect you in the following ways:
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Research Involving Genetic Information,Bullet- Health insurance companies and group health plans may not request your genetic information that we get from this research or use your genetic information when making decisions regarding your eligibility or premiums.,,,yes,yes,"Bullet- Health insurance companies and group health plans may not request your genetic information that we get from this research or use your genetic information when making decisions regarding your eligibility or premiums.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Research Involving Genetic Information,"Bullet- Employers with 15 or more employees may not use your genetic information that we get from this research when making a decision to hire, promote, or fire you or when setting the terms of your employment.",,,yes,yes,"Bullet- Employers with 15 or more employees may not use your genetic information that we get from this research when making a decision to hire, promote, or fire you or when setting the terms of your employment.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Research Involving Genetic Information,"Employers with 15 or more employees, health insurance companies, and group health plans must follow this law. This new law does not protect you against genetic discrimination by companies that sell life insurance, disability insurance, or long-term care insurance.",,,yes,yes,"Employers with 15 or more employees, health insurance companies, and group health plans must follow this law. This new law does not protect you against genetic discrimination by companies that sell life insurance, disability insurance, or long-term care insurance.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Benefits,There is no guarantee that you will receive any benefits from study treatments.,,,yes,yes,"There is no guarantee that you will receive any benefits from study treatments.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Benefits,"Sorafenib and lenvatinib are both approved for the treatment of patients with advanced liver cancer not previously treated with drug therapy. If you receive sorafenib or lenvatinib, benefits may be expected, but there is no guarantee that these drugs will work for you. You might not benefit from the treatment, but you will still receive the standard of care for your disease.",,,yes,yes,"Sorafenib and lenvatinib are both approved for the treatment of patients with advanced liver cancer not previously treated with drug therapy. If you receive sorafenib or lenvatinib, benefits may be expected, but there is no guarantee that these drugs will work for you. You might not benefit from the treatment, but you will still receive the standard of care for your disease.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Benefits,"Nivolumab alone has been approved by the US FDA for the treatment of patients with advanced liver cancer who have been previously treated with sorafenib. However, the benefit of the combination nivolumab plus ipilimumab followed by nivolumab alone has not yet been proven in liver cancer. The investigational treatment may be an effective treatment to delay the growth of your cancer, but it is also possible that you do not have the expected benefit. You might not benefit from the treatment but still receive careful monitoring of your physical condition, frequent visits with a study doctor, and the opportunity to help others by contributing to a scientific investigation.",,,yes,yes,"Nivolumab alone has been approved by the US FDA for the treatment of patients with advanced liver cancer who have been previously treated with sorafenib. However, the benefit of the combination nivolumab plus ipilimumab followed by nivolumab alone has not yet been proven in liver cancer. The investigational treatment may be an effective treatment to delay the growth of your cancer, but it is also possible that you do not have the expected benefit. You might not benefit from the treatment but still receive careful monitoring of your physical condition, frequent visits with a study doctor, and the opportunity to help others by contributing to a scientific investigation.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Benefits,"Your condition will be checked as long as your participation in the study lasts. However, services provided and evaluations carried out as part of the study should not be seen as a substitute for a careful evaluation, ongoing medical care, or follow up by your primary doctor.",,,yes,yes,"Your condition will be checked as long as your participation in the study lasts. However, services provided and evaluations carried out as part of the study should not be seen as a substitute for a careful evaluation, ongoing medical care, or follow up by your primary doctor.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Alternatives,If you decide not to be in the study the study doctor will discuss with you other treatment options and inform you about the alternative treatmentsÃ¢ÂÂ risks and benefits as well. Other treatments options for your condition include:,,,yes,yes,"If you decide not to be in the study the study doctor will discuss with you other treatment options and inform you about the alternative treatmentsÃ¢ÂÂ risks and benefits as well. Other treatments options for your condition include:
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Alternatives,Bullet- Getting treatment or care for your cancer without being in a study,,,yes,yes,"Bullet- Getting treatment or care for your cancer without being in a study
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Alternatives,Bullet- Taking part in another study of an investigational drug. This might have different risks and benefit depending on the other study.,,,yes,yes,"Bullet- Taking part in another study of an investigational drug. This might have different risks and benefit depending on the other study.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Research Related Injury,"If you are injured by being in this research study, the study doctor will arrange for you to get medical treatment. The sponsor will pay for any reasonable medical costs related to the treatment of your injury. If you are injured, there is no money set aside for lost wages, discomfort, disability, etc. You do not give up your legal rights by signing this form. If you think you have a research related injury, please call your study doctor, Dr. Vivek Sharma at (502) 562-4370.",,,yes,yes,"If you are injured by being in this research study, the study doctor will arrange for you to get medical treatment. The sponsor will pay for any reasonable medical costs related to the treatment of your injury. If you are injured, there is no money set aside for lost wages, discomfort, disability, etc. You do not give up your legal rights by signing this form. If you think you have a research related injury, please call your study doctor, Dr. Vivek Sharma at (502) 562-4370.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Payment,"You will be reimbursed for reasonable travel expenses due to your participation in this study. If you are traveling greater than 150 miles roundtrip sponsor approval is required before consenting. You may be reimbursed for reasonable travel expenses like meals, lodging and parking while you are in this study. You must keep the receipts of travel expenses and provide them to your study nurse or team.",,,yes,yes,"You will be reimbursed for reasonable travel expenses due to your participation in this study. If you are traveling greater than 150 miles roundtrip sponsor approval is required before consenting. You may be reimbursed for reasonable travel expenses like meals, lodging and parking while you are in this study. You must keep the receipts of travel expenses and provide them to your study nurse or team.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Payment,"You will be issued a Greenphire ClinCard, which is a specially designed debit card for clinical research onto which your reimbursement funds will be loaded as appropriate. When a visit is completed, funds will be approved and loaded onto your card. The funds will be available within 1 business day. You will be issued one card for the duration of your participation. If your card is lost or stolen a replacement card will be provided. In order for Greenphire to be able to reimburse you via ClinCard, Greenphire will need to collect information about you, including name, address and date of birth. This information will be collected from you by the staff at your study doctorÃ¢ÂÂs site.",,,yes,yes,"You will be issued a Greenphire ClinCard, which is a specially designed debit card for clinical research onto which your reimbursement funds will be loaded as appropriate. When a visit is completed, funds will be approved and loaded onto your card. The funds will be available within 1 business day. You will be issued one card for the duration of your participation. If your card is lost or stolen a replacement card will be provided. In order for Greenphire to be able to reimburse you via ClinCard, Greenphire will need to collect information about you, including name, address and date of birth. This information will be collected from you by the staff at your study doctorÃ¢ÂÂs site.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Payment,All information is stored in a secure fashion and conforms to applicable Privacy and Data Protection requirements of your country or local regulation. Your information will not be shared with any third parties (including Bristol-Myers Squibb) and will be kept completely confidential.,,,yes,yes,"All information is stored in a secure fashion and conforms to applicable Privacy and Data Protection requirements of your country or local regulation. Your information will not be shared with any third parties (including Bristol-Myers Squibb) and will be kept completely confidential.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Payment,Your information will be deleted once the study has been completed and the funds on your card have been spent.,,,yes,yes,"Your information will be deleted once the study has been completed and the funds on your card have been spent.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Payment,"Also, you will have the option to receive updates related to appointment reminders and payment alerts via text message (standard text messaging rates will apply) or email message. You will have the opportunity to opt-in to receive these messages. In order to send you the messages, Greenphire will need your cell phone number and/or e-mail address. You are not required to provide your cell phone or email address to be enrolled in the study or to use a ClinCard. If you choose to receive messages and decide at a later date that you want to stop these messages, you will have the ability to opt-out.",,,yes,yes,"Also, you will have the option to receive updates related to appointment reminders and payment alerts via text message (standard text messaging rates will apply) or email message. You will have the opportunity to opt-in to receive these messages. In order to send you the messages, Greenphire will need your cell phone number and/or e-mail address. You are not required to provide your cell phone or email address to be enrolled in the study or to use a ClinCard. If you choose to receive messages and decide at a later date that you want to stop these messages, you will have the ability to opt-out.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Payment,"By registering with the ClinCard system and using the ClinCard, you consent to participate in the ClinCard program.",,,yes,yes,"By registering with the ClinCard system and using the ClinCard, you consent to participate in the ClinCard program.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Payment,You can still be in the study even if you donÃ¢ÂÂt want to be paid.,,,yes,yes,"You can still be in the study even if you donÃ¢ÂÂt want to be paid.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Costs,You will not be billed for:,,,yes,yes,"You will not be billed for:
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Costs,"Bullet- The study drug(s) nivolumab, the combination of nivolumab and ipilimumab, sorafenib and lenvatinib (and study drug administration for nivolumab and ipilimumab)",,,yes,yes,"Bullet- The study drug(s) nivolumab, the combination of nivolumab and ipilimumab, sorafenib and lenvatinib (and study drug administration for nivolumab and ipilimumab)
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Costs,"Bullet- Additional visits, tests or procedures that are required solely for this study (ask the study staff to discuss these with you)",,,yes,yes,"Bullet- Additional visits, tests or procedures that are required solely for this study (ask the study staff to discuss these with you)
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Costs,The charges for these items will be paid for by the Sponsor.,,,yes,yes,"The charges for these items will be paid for by the Sponsor.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Costs,"You or your insurance company will be billed for all office visits, tests, medications and procedures that are part of your routine medical care. You will be responsible for paying your co-pay that is associated with any office visit, test, medication or procedure that is part of your routine medical care. Some insurance companies will not pay for medical bills for people who participate in a research study. It is your responsibility to find out what costs, if any, your insurance company will cover before taking part in the study. If you have a cancer insurance policy, you will be responsible for checking what coverage, if any, that policy may provide for you if you receive treatment as part of this clinical trial. If you need help finding out what your insurance company will cover, please ask your study doctor for assistance. If your insurance company does not pay for your bills associated with this study, you will be responsible for paying them.",,,yes,yes,"You or your insurance company will be billed for all office visits, tests, medications and procedures that are part of your routine medical care. You will be responsible for paying your co-pay that is associated with any office visit, test, medication or procedure that is part of your routine medical care. Some insurance companies will not pay for medical bills for people who participate in a research study. It is your responsibility to find out what costs, if any, your insurance company will cover before taking part in the study. If you have a cancer insurance policy, you will be responsible for checking what coverage, if any, that policy may provide for you if you receive treatment as part of this clinical trial. If you need help finding out what your insurance company will cover, please ask your study doctor for assistance. If your insurance company does not pay for your bills associated with this study, you will be responsible for paying them.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Costs,"According to Kentucky State Law (KRS Chapter 304.17A-136, Coverage for Cancer Clinical Trials) insurance plans may not deny coverage for routine treatment costs incurred during your participation in a cancer study if your insurance plan would have covered those costs had you not been in the study. This law is for your protection. For more information about this law, ask your study doctor.",,,yes,yes,"According to Kentucky State Law (KRS Chapter 304.17A-136, Coverage for Cancer Clinical Trials) insurance plans may not deny coverage for routine treatment costs incurred during your participation in a cancer study if your insurance plan would have covered those costs had you not been in the study. This law is for your protection. For more information about this law, ask your study doctor.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
HIPAA Research Authorization,"The Health Insurance Portability and Accountability Act of 1996 (HIPAA) provides federal safeguards for your protected health information (PHI). State and federal privacy laws also may also require your health information to be protected. By signing this form you provide your permission, called your Ã¢ÂÂauthorization,Ã¢ÂÂ for the use and disclosure of PHI.",,,yes,yes,"The Health Insurance Portability and Accountability Act of 1996 (HIPAA) provides federal safeguards for your protected health information (PHI). State and federal privacy laws also may also require your health information to be protected. By signing this form you provide your permission, called your Ã¢ÂÂauthorization,Ã¢ÂÂ for the use and disclosure of PHI.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
HIPAA Research Authorization,"If you sign this form, the research team working on this study will use and share your health information to answer the research questions described in this document, and to make sure that the research was done correctly. This includes things learned from the procedures described in this consent form. They may also collect other information including your name, address, date of birth, medical history, and other information from your medical records from this institution and other institutions involved with this research, as well as from your other healthcare providers (which may include information about HIV status, drug, alcohol or sexually transmitted disease treatment, genetic test results, or mental health treatment).",,,yes,yes,"If you sign this form, the research team working on this study will use and share your health information to answer the research questions described in this document, and to make sure that the research was done correctly. This includes things learned from the procedures described in this consent form. They may also collect other information including your name, address, date of birth, medical history, and other information from your medical records from this institution and other institutions involved with this research, as well as from your other healthcare providers (which may include information about HIV status, drug, alcohol or sexually transmitted disease treatment, genetic test results, or mental health treatment).
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
HIPAA Research Authorization,"Those persons who receive your health information may not be required by Federal privacy laws (such as the HIPAA Privacy Rule) to protect it and may share your information with others without your permission, if permitted by laws governing them.",,,yes,yes,"Those persons who receive your health information may not be required by Federal privacy laws (such as the HIPAA Privacy Rule) to protect it and may share your information with others without your permission, if permitted by laws governing them.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
HIPAA Research Authorization,"In most cases, the health information that identifies you can be used or shared by the research team only if you give your permission by signing this form. Your health information may be shared with a public health authority that is authorized by law to collect or receive such information for the purpose of preventing or controlling disease, injury, or disability, and conducting public health surveillance, investigations or interventions.",,,yes,yes,"In most cases, the health information that identifies you can be used or shared by the research team only if you give your permission by signing this form. Your health information may be shared with a public health authority that is authorized by law to collect or receive such information for the purpose of preventing or controlling disease, injury, or disability, and conducting public health surveillance, investigations or interventions.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
HIPAA Research Authorization,"According to legal requirements, your personal data collected as part of this study will be stored in the study databases and/or paper files for whichever time period is longer, as required by applicable laws:",,,yes,yes,"According to legal requirements, your personal data collected as part of this study will be stored in the study databases and/or paper files for whichever time period is longer, as required by applicable laws:
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
HIPAA Research Authorization,"Bullet- at least 15 years after the study ends, OR",,,yes,yes,"Bullet- at least 15 years after the study ends, OR
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
HIPAA Research Authorization,"Bullet- at least 2 years after the drug being studied has received its last approval for sale, OR",,,yes,yes,"Bullet- at least 2 years after the drug being studied has received its last approval for sale, OR
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
HIPAA Research Authorization,Bullet- at least 2 years after the drugÃ¢ÂÂs development has stopped.,,,yes,yes,"Bullet- at least 2 years after the drugÃ¢ÂÂs development has stopped.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
HIPAA Research Authorization,Your permission and authorization to use and share your protected health information is not limited in any way by the storage requirements above or the timelines associated with them. Your permission does not expire unless you revoke or cancel it.,,,yes,yes,"Your permission and authorization to use and share your protected health information is not limited in any way by the storage requirements above or the timelines associated with them. Your permission does not expire unless you revoke or cancel it.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
HIPAA Research Authorization,"Some information collected about you only for this research study may be kept in a research study record separate from your medical record, and some research information may also be part of your medical record. You will not have access to this research information until the end of the study. However, it will be available to your physicians if needed for your care.",,,yes,yes,"Some information collected about you only for this research study may be kept in a research study record separate from your medical record, and some research information may also be part of your medical record. You will not have access to this research information until the end of the study. However, it will be available to your physicians if needed for your care.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
HIPAA Research Authorization,"You do not have to sign this form. If you do not sign this form, you may not participate in the study and health information that identifies you will not be shared for research purposes.",,,yes,yes,"You do not have to sign this form. If you do not sign this form, you may not participate in the study and health information that identifies you will not be shared for research purposes.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Revocation of Research Authorization,You may withdraw the authorization you have given to use and share your protected health information at any time. This means you can tell us to stop using and sharing your protected health information.  If you cancel your permission:,,,yes,yes,"You may withdraw the authorization you have given to use and share your protected health information at any time. This means you can tell us to stop using and sharing your protected health information.  If you cancel your permission:
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Revocation of Research Authorization,Bullet- We will stop collecting information about you.,,,yes,yes,"Bullet- We will stop collecting information about you.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Revocation of Research Authorization,Bullet- You may not withdraw information that we had before you told us to stop.,,,yes,yes,"Bullet- You may not withdraw information that we had before you told us to stop.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Revocation of Research Authorization,Bullet- We may already have used it or shared it.,,,yes,yes,"Bullet- We may already have used it or shared it.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Revocation of Research Authorization,Bullet- We may need it to complete the research.,,,yes,yes,"Bullet- We may need it to complete the research.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Revocation of Research Authorization,Bullet- We may need it to search records that are available to the public.,,,yes,yes,"Bullet- We may need it to search records that are available to the public.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Revocation of Research Authorization,Bullet- Staff may ask your permission to follow-up with you if there is a medical reason to do so.,,,yes,yes,"Bullet- Staff may ask your permission to follow-up with you if there is a medical reason to do so.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Revocation of Research Authorization,"To cancel your permission, you will be requested to complete a written Ã¢ÂÂRevocation of Research AuthorizationÃ¢ÂÂ form located at the end of this document. You may also obtain a copy from your study doctor, designated personnel or from the Human Subjects Protections Program Office website (https://louisville.edu/research/humansubjects/templates/biomedical- forms).",,,yes,yes,"To cancel your permission, you will be requested to complete a written Ã¢ÂÂRevocation of Research AuthorizationÃ¢ÂÂ form located at the end of this document. You may also obtain a copy from your study doctor, designated personnel or from the Human Subjects Protections Program Office website (https://louisville.edu/research/humansubjects/templates/biomedical- forms).
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Information Available on ClinicalTrials.gov,"A description of this clinical trial will be available on , as required by U.S. Law. This website will not include information that can identify you. At most, the website will include a summary of the results. You can search this website at any time.",,,yes,yes,"A description of this clinical trial will be available on , as required by U.S. Law. This website will not include information that can identify you. At most, the website will include a summary of the results. You can search this website at any time.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Confidentiality,"Total privacy cannot be guaranteed. We will protect your privacy to the extent permitted by law. If the results from this study are published, your name will not be made public. Once your information leaves our institution, we cannot promise that others will keep it private.",,,yes,yes,"Total privacy cannot be guaranteed. We will protect your privacy to the extent permitted by law. If the results from this study are published, your name will not be made public. Once your information leaves our institution, we cannot promise that others will keep it private.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Confidentiality,Your information may be shared with the following:,,,yes,yes,"Your information may be shared with the following:
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Confidentiality,Bullet- The sponsor Bristol-Myers Squibb and others hired by the sponsor to oversee the research,,,yes,yes,"Bullet- The sponsor Bristol-Myers Squibb and others hired by the sponsor to oversee the research
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Confidentiality,Bullet- Organizations that provide funding at any time for the conduct of the research.,,,yes,yes,"Bullet- Organizations that provide funding at any time for the conduct of the research.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Confidentiality,"Bullet- The University of Louisville Institutional Review Board, Human Subjects Protection Program Office, Privacy Office, others involved in research administration and compliance at the University, and others contracted by the University for ensuring human subjects safety or research compliance",,,yes,yes,"Bullet- The University of Louisville Institutional Review Board, Human Subjects Protection Program Office, Privacy Office, others involved in research administration and compliance at the University, and others contracted by the University for ensuring human subjects safety or research compliance
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Confidentiality,Bullet- The local research team,,,yes,yes,"Bullet- The local research team
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Confidentiality,"Bullet- People who are responsible for research, compliance and HIPAA oversight at the institutions where the research is conducted",,,yes,yes,"Bullet- People who are responsible for research, compliance and HIPAA oversight at the institutions where the research is conducted
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Confidentiality,"Bullet- People responsible for billing, sending and receiving payments related to your participation in the study",,,yes,yes,"Bullet- People responsible for billing, sending and receiving payments related to your participation in the study
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Confidentiality,"Bullet- Government agencies, such as:",,,yes,yes,"Bullet- Government agencies, such as:
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Confidentiality,Bullet- Office for Human Research Protections,,,yes,yes,"Bullet- Office for Human Research Protections
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Confidentiality,Bullet- Office of Civil Rights,,,yes,yes,"Bullet- Office of Civil Rights
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Confidentiality,Bullet- Food and Drug Administration,,,yes,yes,"Bullet- Food and Drug Administration
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Confidentiality,Bullet- Those responsible for data safety monitoring related to the study,,,yes,yes,"Bullet- Those responsible for data safety monitoring related to the study
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Confidentiality,"Bullet- Other individuals and organizations that analyze or use your information in connection with these research activities, including laboratories and study sites (in the event you transfer to another study site);",,,yes,yes,"Bullet- Other individuals and organizations that analyze or use your information in connection with these research activities, including laboratories and study sites (in the event you transfer to another study site);
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Confidentiality,"For the purposes of your participation in this study and the protection of your identity, your study doctor will assign you a unique code, such as a series of numbers and/or letters. The study doctor will record the study data collected from you in a report form that uses your assigned code, not your name. This is to protect your data by making it anonymous for most study purposes.",,,yes,yes,"For the purposes of your participation in this study and the protection of your identity, your study doctor will assign you a unique code, such as a series of numbers and/or letters. The study doctor will record the study data collected from you in a report form that uses your assigned code, not your name. This is to protect your data by making it anonymous for most study purposes.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Confidentiality,The data that is recorded with your assigned code rather than your name is called Ã¢ÂÂkey-coded dataÃ¢ÂÂ. The key-coded data will be entered into the studyÃ¢ÂÂs computer database. Your study doctor will keep a confidential list linking your name to your code and only authorized persons will have access to this list.,,,yes,yes,"The data that is recorded with your assigned code rather than your name is called Ã¢ÂÂkey-coded dataÃ¢ÂÂ. The key-coded data will be entered into the studyÃ¢ÂÂs computer database. Your study doctor will keep a confidential list linking your name to your code and only authorized persons will have access to this list.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Security,"Your information will be kept private by password protected computers and storage in limited access, locked areas.",,,yes,yes,"Your information will be kept private by password protected computers and storage in limited access, locked areas.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Conflict of Interest,"This study involves a conflict of interest because the institution will be compensated for your participation. This compensation is used to pay for the costs of doing this study including sending research data to the sponsor. If you want to know, please ask the study doctor how the institution will benefit by your participation in the study.",,,yes,yes,"This study involves a conflict of interest because the institution will be compensated for your participation. This compensation is used to pay for the costs of doing this study including sending research data to the sponsor. If you want to know, please ask the study doctor how the institution will benefit by your participation in the study.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Voluntary Participation,"Taking part in this study is completely voluntary. You may choose not to take part at all. If you decide not to be in this study, you wonÃ¢ÂÂt be penalized or lose any benefits for which you qualify. If you decide to be in this study, you may change your mind and stop taking part at any time. If you decide to stop taking part, you wonÃ¢ÂÂt be penalized or lose any benefits for which you qualify. You will be told about any new information learned during the study that could affect your decision to continue in the study.",,,yes,yes,"Taking part in this study is completely voluntary. You may choose not to take part at all. If you decide not to be in this study, you wonÃ¢ÂÂt be penalized or lose any benefits for which you qualify. If you decide to be in this study, you may change your mind and stop taking part at any time. If you decide to stop taking part, you wonÃ¢ÂÂt be penalized or lose any benefits for which you qualify. You will be told about any new information learned during the study that could affect your decision to continue in the study.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Termination,"Your study doctor or the study sponsor has the right to stop this study at any point. Your study doctor may take you out of this study with or without your okay if they feel this is in your best interest. the Sponsor may also decide to stop the study without your consent. If this happens, the reason will be explained to you. Should this happen, your study doctor will decide the best course of treatment for you.",,,yes,yes,"Your study doctor or the study sponsor has the right to stop this study at any point. Your study doctor may take you out of this study with or without your okay if they feel this is in your best interest. the Sponsor may also decide to stop the study without your consent. If this happens, the reason will be explained to you. Should this happen, your study doctor will decide the best course of treatment for you.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Participation in Other Research Studies,You may not take part in this study if you are currently in another therapeutic study. It is important to let your study doctor know if you are in another research study.,,,yes,yes,"You may not take part in this study if you are currently in another therapeutic study. It is important to let your study doctor know if you are in another research study.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Research SubjectÃ¢ÂÂs Rights,"If you have any questions about your rights as a research subject, you may call the Human Subjects Protection Program Office at (502) 852-5188. You may discuss any questions about your rights as a research subject, in private, with a member of the Institutional Review Board (IRB). You may also call this number if you have other questions about the research, and you cannot reach the study doctor, or want to talk to someone else. The IRB is an independent committee made up of people from the University community, staff of the institutions, as well as people from the community not connected with these institutions. The IRB has approved the participation of human subjects in this research study.",,,yes,yes,"If you have any questions about your rights as a research subject, you may call the Human Subjects Protection Program Office at (502) 852-5188. You may discuss any questions about your rights as a research subject, in private, with a member of the Institutional Review Board (IRB). You may also call this number if you have other questions about the research, and you cannot reach the study doctor, or want to talk to someone else. The IRB is an independent committee made up of people from the University community, staff of the institutions, as well as people from the community not connected with these institutions. The IRB has approved the participation of human subjects in this research study.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
"Questions, Concerns and Complaints","If you have any questions about the research study, please contact Dr. Vivek Sharma at (502) 562-4370.",,,yes,yes,"If you have any questions about the research study, please contact Dr. Vivek Sharma at (502) 562-4370.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
"Questions, Concerns and Complaints","If you have concerns or complaints about the research or research staff and you do not wish to give your name, you may call the toll free number 1-877-852-1167. This is a 24 hour hot line answered by people who do not work at the University of Louisville.",,,yes,yes,"If you have concerns or complaints about the research or research staff and you do not wish to give your name, you may call the toll free number 1-877-852-1167. This is a 24 hour hot line answered by people who do not work at the University of Louisville.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Please note: This section of the informed consent form is about additional research that is being done with people who are taking part in the main study. You may take part in this additional research if you want to. You can still be a part of the main study even if you say Ã¢ÂÂnoÃ¢ÂÂ to taking part in this additional research,"The mission of Bristol-Myers Squibb (BMS) is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases, such as cancer, heart disease, hepatitis, and HIV/AIDS. The researchers at BMS need to use tissue, blood, or other samples and information from a wide variety of people to do this research. This is only possible because people like you volunteer to donate the samples. Thank you for considering the information in this consent form to decide whether you would like to agree to the collection, storage and use of samples and health information for research.",,,yes,yes,"The mission of Bristol-Myers Squibb (BMS) is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases, such as cancer, heart disease, hepatitis, and HIV/AIDS. The researchers at BMS need to use tissue, blood, or other samples and information from a wide variety of people to do this research. This is only possible because people like you volunteer to donate the samples. Thank you for considering the information in this consent form to decide whether you would like to agree to the collection, storage and use of samples and health information for research.
I agree to the above statement",Certificate,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
What is the purpose of this consent form?,This consent form gives you information so that you can decide whether you want to agree to:,,,yes,yes,"This consent form gives you information so that you can decide whether you want to agree to:
I agree to the above statement",Certificate,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
What is the purpose of this consent form?,"Bullet- Allow the BMS researchers to store your collected samples and medical information, and use them for various research projects; and",,,yes,yes,"Bullet- Allow the BMS researchers to store your collected samples and medical information, and use them for various research projects; and
I agree to the above statement",Certificate,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
What is the purpose of this consent form?,Bullet- Allow the BMS researchers to transfer these samples and information to external researchers for use in specific research projects.,,,yes,yes,"Bullet- Allow the BMS researchers to transfer these samples and information to external researchers for use in specific research projects.
I agree to the above statement",Certificate,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
What is the purpose of this consent form?,"Please read this section carefully and take your time making your decision about agreeing to donate samples and information for BMS research activities. Be sure to ask about anything that does not seem clear. You should feel free to talk over your decision with your family, friends, doctor, and health care team.",,,yes,yes,"Please read this section carefully and take your time making your decision about agreeing to donate samples and information for BMS research activities. Be sure to ask about anything that does not seem clear. You should feel free to talk over your decision with your family, friends, doctor, and health care team.
I agree to the above statement",Certificate,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Definitions for key words used in this consent form,The terms below will be in bold or italics when used in this consent form.,,,yes,yes,"The terms below will be in bold or italics when used in this consent form.
I agree to the above statement",Certificate,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Definitions for key words used in this consent form,"BMS researchers Ã¢ÂÂ BMS, its current and future affiliates, and those working on their behalf, who will store samples and information collected from you and use them in additional research. BMS researchers also include any companies that work in collaboration with BMS or take over some or all of BMSÃ¢ÂÂs business.",,,yes,yes,"BMS researchers Ã¢ÂÂ BMS, its current and future affiliates, and those working on their behalf, who will store samples and information collected from you and use them in additional research. BMS researchers also include any companies that work in collaboration with BMS or take over some or all of BMSÃ¢ÂÂs business.
I agree to the above statement",Certificate,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Definitions for key words used in this consent form,"External researchers Ã¢ÂÂ Any other person or organization to whom BMS researchers transfer samples or information for use in the external researcherÃ¢ÂÂs additional research. External researchers may include, for example, academic scientists, or companies working with BMS to develop drugs.",,,yes,yes,"External researchers Ã¢ÂÂ Any other person or organization to whom BMS researchers transfer samples or information for use in the external researcherÃ¢ÂÂs additional research. External researchers may include, for example, academic scientists, or companies working with BMS to develop drugs.
I agree to the above statement",Certificate,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Definitions for key words used in this consent form,Additional research Ã¢ÂÂ The types of research described below under Ã¢ÂÂWhat will happen during these research activities and what do I need to do?Ã¢ÂÂ Additional research will occur in the future and will use the stored samples and information collected from you.,,,yes,yes,"Additional research Ã¢ÂÂ The types of research described below under Ã¢ÂÂWhat will happen during these research activities and what do I need to do?Ã¢ÂÂ Additional research will occur in the future and will use the stored samples and information collected from you.
I agree to the above statement",Certificate,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Definitions for key words used in this consent form,"Personal health information (PHI) Ã¢ÂÂ This includes records that identify you, and may include, but is not limited to, your name, address, telephone number, date of birth, and medical information collected for the additional research.",,,yes,yes,"Personal health information (PHI) Ã¢ÂÂ This includes records that identify you, and may include, but is not limited to, your name, address, telephone number, date of birth, and medical information collected for the additional research.
I agree to the above statement",Certificate,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Definitions for key words used in this consent form,"Samples Ã¢ÂÂ The human samples (such as blood, urine, bodily tissue) already collected from you that will be stored and used in additional research",,,yes,yes,"Samples Ã¢ÂÂ The human samples (such as blood, urine, bodily tissue) already collected from you that will be stored and used in additional research
I agree to the above statement",Certificate,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
What will happen during these research activities and what do I need to do?,"The BMS researchers will use your samples and information, along with those from other people, in additional research.",,,yes,yes,"The BMS researchers will use your samples and information, along with those from other people, in additional research.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
What will happen during these research activities and what do I need to do?,"The information will be collected directly from you, or from your medical records. This may include information such as your age, and racial or ethnic group, your diagnoses, lab results, medical procedures, and medications and other treatments, including how the treatments worked. It may also include information about your family's health history. The samples and information will be given to BMS researchers.",,,yes,yes,"The information will be collected directly from you, or from your medical records. This may include information such as your age, and racial or ethnic group, your diagnoses, lab results, medical procedures, and medications and other treatments, including how the treatments worked. It may also include information about your family's health history. The samples and information will be given to BMS researchers.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
What will happen during these research activities and what do I need to do?,"The term Ã¢ÂÂadditional researchÃ¢ÂÂ when used in this consent form means research that relates to the diagnoses or treatment of disease or other health problems. BMS has a broad and diverse research program, and your donations will be used by BMS researchers, as needed, to understand the causes of diseases and to develop new therapies or tests to diagnose, prevent, and treat diseases.",,,yes,yes,"The term Ã¢ÂÂadditional researchÃ¢ÂÂ when used in this consent form means research that relates to the diagnoses or treatment of disease or other health problems. BMS has a broad and diverse research program, and your donations will be used by BMS researchers, as needed, to understand the causes of diseases and to develop new therapies or tests to diagnose, prevent, and treat diseases.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
What will happen during these research activities and what do I need to do?,"This additional research may involve studying how genes affect health and disease, or how genes affect a bodyÃ¢ÂÂs response to treatment. Genes, which are made of DNA, give the instructions for building all the proteins that make our bodies work. Additional research may analyze some or all of your genes and how they function to understand how diseases develop and how they can be effectively treated. All requests for additional research on samples that are volunteered under this consent will be reviewed by a diverse committee of senior leaders in research and development at BMS to ensure the research is aligned to support well-defined needs of our scientific research and drug development efforts.",,,yes,yes,"This additional research may involve studying how genes affect health and disease, or how genes affect a bodyÃ¢ÂÂs response to treatment. Genes, which are made of DNA, give the instructions for building all the proteins that make our bodies work. Additional research may analyze some or all of your genes and how they function to understand how diseases develop and how they can be effectively treated. All requests for additional research on samples that are volunteered under this consent will be reviewed by a diverse committee of senior leaders in research and development at BMS to ensure the research is aligned to support well-defined needs of our scientific research and drug development efforts.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
What will happen during these research activities and what do I need to do?,The BMS researchers may also transfer the samples and information to external researchers for their use in additional research.,,,yes,yes,"The BMS researchers may also transfer the samples and information to external researchers for their use in additional research.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
What will happen during these research activities and what do I need to do?,External researchers may ask BMS for samples and information for use in their own research. BMS researchers will agree to transfer the samples and information only to external researchers who agree to use them solely for additional research and agree to conduct the additional research under the terms specified by BMS to ensure that the information conveyed to you in this consent form is enforced.,,,yes,yes,"External researchers may ask BMS for samples and information for use in their own research. BMS researchers will agree to transfer the samples and information only to external researchers who agree to use them solely for additional research and agree to conduct the additional research under the terms specified by BMS to ensure that the information conveyed to you in this consent form is enforced.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
How long will the samples and information be stored?,"Samples kept for additional research will be stored at the BMS Biorepository in NJ, USA or an independent, BMS-approved storage vendor. The manager of these samples will ensure they",,,yes,yes,"Samples kept for additional research will be stored at the BMS Biorepository in NJ, USA or an independent, BMS-approved storage vendor. The manager of these samples will ensure they
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
How long will the samples and information be stored?,"are properly used throughout their usable life and will destroy the samples at the end of the scheduled storage period, no longer than fifteen (15) years after the end of the study.",,,yes,yes,"are properly used throughout their usable life and will destroy the samples at the end of the scheduled storage period, no longer than fifteen (15) years after the end of the study.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
How long will the samples and information be stored?,Your options for stopping the use of the samples and information collected from you is described below under Ã¢ÂÂWhat if I change my mind about participating in the research activities?Ã¢ÂÂ,,,yes,yes,"Your options for stopping the use of the samples and information collected from you is described below under Ã¢ÂÂWhat if I change my mind about participating in the research activities?Ã¢ÂÂ
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
What are the discomforts or possible risks?,"Your residual tumor tissue and blood samples will be used for the additional research, so",,,yes,yes,"Your residual tumor tissue and blood samples will be used for the additional research, so
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
What are the discomforts or possible risks?,there are no additional risks or discomforts.,,,yes,yes,"there are no additional risks or discomforts.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
What are the discomforts or possible risks?,"Special precautions have been put in place to protect the security of your samples and information. However, despite these precautions, there is a possible risk that someone other than those described in this consent form could get access to the samples and information that you provide. BMS researchers believe the chance of this happening is small. However, it is not possible to guarantee that it wonÃ¢ÂÂt happen. If a sample or information suggested something serious about your health, it could be misused. For example, it could be used to make it harder for you to get or keep a job or insurance. There are laws against this kind of misuse, but they may not give full protection.",,,yes,yes,"Special precautions have been put in place to protect the security of your samples and information. However, despite these precautions, there is a possible risk that someone other than those described in this consent form could get access to the samples and information that you provide. BMS researchers believe the chance of this happening is small. However, it is not possible to guarantee that it wonÃ¢ÂÂt happen. If a sample or information suggested something serious about your health, it could be misused. For example, it could be used to make it harder for you to get or keep a job or insurance. There are laws against this kind of misuse, but they may not give full protection.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
What are the discomforts or possible risks?,Your privacy and the confidentiality of your medical information and samples are very important to the BMS researchers and they will make every effort to protect them. These efforts are described in the section Ã¢ÂÂHow will my privacy be protectedÃ¢ÂÂ.,,,yes,yes,"Your privacy and the confidentiality of your medical information and samples are very important to the BMS researchers and they will make every effort to protect them. These efforts are described in the section Ã¢ÂÂHow will my privacy be protectedÃ¢ÂÂ.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
What are the discomforts or possible risks?,"Additional research may involve your genetic information. In the U.S., a Federal law, called the Genetic Information Nondiscrimination Act (GINA), generally makes it illegal for health insurance companies, group health plans, and most employers to discriminate against you based on your genetic information. This law generally is meant to protect you in the following ways:",,,yes,yes,"Additional research may involve your genetic information. In the U.S., a Federal law, called the Genetic Information Nondiscrimination Act (GINA), generally makes it illegal for health insurance companies, group health plans, and most employers to discriminate against you based on your genetic information. This law generally is meant to protect you in the following ways:
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
What are the discomforts or possible risks?,Bullet- Health insurance companies and group health plans may not request your genetic information that may be derived from additional research.,,,yes,yes,"Bullet- Health insurance companies and group health plans may not request your genetic information that may be derived from additional research.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
What are the discomforts or possible risks?,Bullet- Health insurance companies and group health plans may not use your genetic information when making decisions regarding your eligibility or premiums.,,,yes,yes,"Bullet- Health insurance companies and group health plans may not use your genetic information when making decisions regarding your eligibility or premiums.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
What are the discomforts or possible risks?,"Bullet- If employers somehow obtain your genetic information, employers with 15 or more employees may not use any genetic information derived from additional research when making a decision to hire, promote, or fire you or when setting the terms of your employment.",,,yes,yes,"Bullet- If employers somehow obtain your genetic information, employers with 15 or more employees may not use any genetic information derived from additional research when making a decision to hire, promote, or fire you or when setting the terms of your employment.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
What are the discomforts or possible risks?,"Be aware that this Federal law does not protect you against genetic discrimination by companies that sell life insurance, disability insurance, or long-term care insurance.",,,yes,yes,"Be aware that this Federal law does not protect you against genetic discrimination by companies that sell life insurance, disability insurance, or long-term care insurance.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
How will my privacy be protected?,BMS researchers and external researchers take your privacy very seriously. They will take the following steps to protect your privacy.,,,yes,yes,"BMS researchers and external researchers take your privacy very seriously. They will take the following steps to protect your privacy.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
How will my privacy be protected?,"The samples and information that the study doctor and medical personnel provide to the BMS researchers will be identified with a code number - not your name. The study doctor will keep your name and anything else that is intended to identify you securely in a separate file with limited access. The study doctor will maintain the master list that links the code number to your name, this master list will not be shared with BMS researchers.",,,yes,yes,"The samples and information that the study doctor and medical personnel provide to the BMS researchers will be identified with a code number - not your name. The study doctor will keep your name and anything else that is intended to identify you securely in a separate file with limited access. The study doctor will maintain the master list that links the code number to your name, this master list will not be shared with BMS researchers.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
BMS Researchers:,"As we noted earlier, BMS Researchers will not be given information meant to identify you. They will receive only samples and information identified by a code number. The BMS researchers will also not be given the master list. The BMS researchers will not try to identify you.",,,yes,yes,"As we noted earlier, BMS Researchers will not be given information meant to identify you. They will receive only samples and information identified by a code number. The BMS researchers will also not be given the master list. The BMS researchers will not try to identify you.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
BMS Researchers:,The BMS researchers store samples in secured freezers in locked buildings. The primary storage location is in the United States. Only authorized persons have access to these locations. The BMS researchers may also use storage partners to securely store some samples when more storage room is needed or when required by the law. The information that you provide and the data obtained from additional research will be stored on secure computers.,,,yes,yes,"The BMS researchers store samples in secured freezers in locked buildings. The primary storage location is in the United States. Only authorized persons have access to these locations. The BMS researchers may also use storage partners to securely store some samples when more storage room is needed or when required by the law. The information that you provide and the data obtained from additional research will be stored on secure computers.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
BMS Researchers:,"At some point, the results of additional research may be published, but you will not be identified by name in any of these publications.",,,yes,yes,"At some point, the results of additional research may be published, but you will not be identified by name in any of these publications.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
External Researchers:,"BMS researchers will transfer the samples and information only to external researchers who have agreed to store, secure and use the samples and information and protect your privacy at least to the same standards as BMS researchers will do as described in this consent form.",,,yes,yes,"BMS researchers will transfer the samples and information only to external researchers who have agreed to store, secure and use the samples and information and protect your privacy at least to the same standards as BMS researchers will do as described in this consent form.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Other important information:,"BMS researchers and external researchers may transfer the samples, information and results to persons or companies located outside of the country or region where you live.",,,yes,yes,"BMS researchers and external researchers may transfer the samples, information and results to persons or companies located outside of the country or region where you live.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Other important information:,It is possible that members of regulatory authorities such as the United States Food and Drug Administration or the European Medicines Agency and other persons required by law may have access to the samples and information that you provide or the results of additional research.,,,yes,yes,"It is possible that members of regulatory authorities such as the United States Food and Drug Administration or the European Medicines Agency and other persons required by law may have access to the samples and information that you provide or the results of additional research.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Are there any costs to me?,No. There are no costs to you or your health insurance.,,,yes,yes,"No. There are no costs to you or your health insurance.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Will I receive any benefits or payments for providing samples and information for additional research?,"You will not be paid, nor should you expect any direct benefit for providing samples and information for additional research, but additional research may add to the knowledge and understanding of medical conditions and how different people respond to drugs, or help in the development of new methods to diagnose and treat diseases.",,,yes,yes,"You will not be paid, nor should you expect any direct benefit for providing samples and information for additional research, but additional research may add to the knowledge and understanding of medical conditions and how different people respond to drugs, or help in the development of new methods to diagnose and treat diseases.
I agree to the above statement",Certificate,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Will I receive any benefits or payments for providing samples and information for additional research?,"The samples you provide will not be sold, and the BMS researchers and external researchers will not grow any cells from the samples that you provide.",,,yes,yes,"The samples you provide will not be sold, and the BMS researchers and external researchers will not grow any cells from the samples that you provide.
I agree to the above statement",Certificate,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Will I receive any benefits or payments for providing samples and information for additional research?,"You should know that research, including additional research, can result in discoveries that may one day have commercial value. For example, discoveries could eventually lead to new tests, drugs, or other products. If this happened, you will not share in any of the profits from the sale of any tests, drugs or other products. Development of new products relies on the study of samples and information from hundreds or thousands of people, not on any one person.",,,yes,yes,"You should know that research, including additional research, can result in discoveries that may one day have commercial value. For example, discoveries could eventually lead to new tests, drugs, or other products. If this happened, you will not share in any of the profits from the sale of any tests, drugs or other products. Development of new products relies on the study of samples and information from hundreds or thousands of people, not on any one person.
I agree to the above statement",Certificate,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Will I find out the results of additional research?,No. You will not receive individual results from additional research done with the samples or information that you provide. The results of additional research are experimental; they will not be given to your doctor and will not be put in your medical record. They will only be individually disclosed if required by law.,,,yes,yes,"No. You will not receive individual results from additional research done with the samples or information that you provide. The results of additional research are experimental; they will not be given to your doctor and will not be put in your medical record. They will only be individually disclosed if required by law.
I agree to the above statement",Certificate,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Will I find out the results of additional research?,"You may withdraw this consent at any time and your samples and information will no longer be used for research. The address for sending a letter to withdraw is provided on the Additional Research Sample Withdrawal form. You can request that BMS destroy any remaining samples and information by working with your study doctor who will complete the withdrawal form for destruction of your samples. However, the research information derived from your samples and information will not be destroyed.",,,yes,yes,"You may withdraw this consent at any time and your samples and information will no longer be used for research. The address for sending a letter to withdraw is provided on the Additional Research Sample Withdrawal form. You can request that BMS destroy any remaining samples and information by working with your study doctor who will complete the withdrawal form for destruction of your samples. However, the research information derived from your samples and information will not be destroyed.
I agree to the above statement",Certificate,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Will I find out the results of additional research?,BMS researchers may not be able to destroy samples or information collected from you:,,,yes,yes,"BMS researchers may not be able to destroy samples or information collected from you:
I agree to the above statement",Certificate,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Will I find out the results of additional research?,Bullet- when the BMS researchers have already given the samples and information to,,,yes,yes,"Bullet- when the BMS researchers have already given the samples and information to
I agree to the above statement",Certificate,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Will I find out the results of additional research?,external researchers for use in additional research; or,,,yes,yes,"external researchers for use in additional research; or
I agree to the above statement",Certificate,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Will I find out the results of additional research?,Bullet- when the study doctor no longer has the master list,,,yes,yes,"Bullet- when the study doctor no longer has the master list
I agree to the above statement",Certificate,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Will I find out the results of additional research?,"Also, any knowledge that was already learned from using the samples and information in additional research before receiving notice of your decision to withdraw will not be destroyed by the BMS researchers or external researchers.",,,yes,yes,"Also, any knowledge that was already learned from using the samples and information in additional research before receiving notice of your decision to withdraw will not be destroyed by the BMS researchers or external researchers.
I agree to the above statement",Certificate,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Will I find out the results of additional research?,"If you decide not to participate in the main clinical study, your samples may still be used for additional research unless you specifically revoke that authorization by working with your study doctor as described above.",,,yes,yes,"If you decide not to participate in the main clinical study, your samples may still be used for additional research unless you specifically revoke that authorization by working with your study doctor as described above.
I agree to the above statement",Certificate,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
"If I choose not to sign this consent form, can I still volunteer to donate samples and information?",No.,,,yes,yes,"No.
I agree to the above statement",Certificate,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
What if I have questions?,"You should feel free to ask any questions. Your questions should be answered clearly and to your satisfaction. For questions about your rights as a research volunteer, contact the individual named below. We will give you a signed copy of this consent form to keep.",,,yes,yes,"You should feel free to ask any questions. Your questions should be answered clearly and to your satisfaction. For questions about your rights as a research volunteer, contact the individual named below. We will give you a signed copy of this consent form to keep.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Statement of Consent,"Ã¢ÂÂ¡ Yes, I agree to have my samples and my information be retained, stored and used for 
additional research, as described in this consent",Yes,,yes,yes,"Ã¢ÂÂ¡ Yes, I agree to have my samples and my information be retained, stored and used for 
additional research, as described in this consent
I agree to the above statement",Certificate,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",Yes
Statement of Consent,"Subject Name (Please Print) or	Signature of Subject or legally",,Nafisa Ali,yes,yes,"Subject Name (Please Print) or	Signature of Subject or legally
I agree to the above statement",Certificate,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",Nafisa Ali
Statement of Consent,Date (to be entered by Study participant),,2/5/2023,yes,yes,"Date (to be entered by Study participant)
I agree to the above statement",Certificate,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",2/5/2023
Statement of Consent,"Ã¢ÂÂ¡ No, I do not agree to have my samples and my information be retained, stored and used for additional research, as described in this consent.",No,,yes,no,"Ã¢ÂÂ¡ No, I do not agree to have my samples and my information be retained, stored and used for additional research, as described in this consent.
I do not agree to the above statement",Certificate,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",No
Statement of Consent,"Subject Name (Please Print) or	Signature of Subject or legally",,,yes,yes,"Subject Name (Please Print) or	Signature of Subject or legally
I agree to the above statement",Certificate,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Statement of Consent,Date (to be entered by Study participant),,,yes,yes,"Date (to be entered by Study participant)
I agree to the above statement",Certificate,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
ADDITIONAL RESEARCH SAMPLE WITHDRAWAL,EMAIL TRANSMITTAL SHEET,,,yes,yes,"EMAIL TRANSMITTAL SHEET
I agree to the above statement",Certificate,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
EMAIL THIS COMPLETED PAGE TO:,BMS Biorepository Manager Email:,,,yes,yes,"BMS Biorepository Manager Email:
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
WITHDRAWAL OF PERMISSION FOR USE OF SPECIMENS IN ADDITIONAL RESEARCH,This section is to be completed by either the investigator or the coordinator at the institution.,,,yes,yes,"This section is to be completed by either the investigator or the coordinator at the institution.
I agree to the above statement",Certificate,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
WITHDRAWAL OF PERMISSION FOR USE OF SPECIMENS IN ADDITIONAL RESEARCH,"The study participant indicated below (only identify the study participant using the study participant number; DO NOT provide any other identifying information such as the study participantÃ¢ÂÂs name or social security number) initially provided informed consent for his/her samples to be used for additional research by BMS, itÃ¢ÂÂs current or future affiliates, and those working on their behalf. After discussion with a study staff member at our institution, he/she has now indicated that he/she wants to withdraw consent for additional research by BMS researchers and have his/her sample(s) destroyed and contact information (if provided) removed from any BMS database.",,,yes,yes,"The study participant indicated below (only identify the study participant using the study participant number; DO NOT provide any other identifying information such as the study participantÃ¢ÂÂs name or social security number) initially provided informed consent for his/her samples to be used for additional research by BMS, itÃ¢ÂÂs current or future affiliates, and those working on their behalf. After discussion with a study staff member at our institution, he/she has now indicated that he/she wants to withdraw consent for additional research by BMS researchers and have his/her sample(s) destroyed and contact information (if provided) removed from any BMS database.
I agree to the above statement",Certificate,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
"PROTOCOL NUMBER	SITE NUMBER 		 STUDY PARTICIPANT NUMBER:  	 INVESTIGATOR NAME: 			 INVESTIGATORÃ¢ÂÂS FAX: 				 INVESTIGATOR SIGNATURE:",This section is to be completed by the BMS Biorepository and faxed back to the investigator,,,yes,yes,"This section is to be completed by the BMS Biorepository and faxed back to the investigator
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
CONFIRMATION OF SAMPLE DESTRUCTION,"The sample(s) and related material derived from the sample(s), as well as any contact information obtained from the study participant indicated above, has been destroyed. Please notify the study participant that this has occurred.",,,yes,yes,"The sample(s) and related material derived from the sample(s), as well as any contact information obtained from the study participant indicated above, has been destroyed. Please notify the study participant that this has occurred.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
CONFIRMATION OF SAMPLE DESTRUCTION,"VERIFIED BY:	DATE:	 PRINT NAME:",,,yes,yes,"VERIFIED BY:	DATE:	 PRINT NAME:
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Acknowledgment and Signatures,"This document tells you what will happen during the study if you choose to take part. Your signature and date indicates that you have read and understood this consent form, this study has been explained to you, you have been given the chance to ask any questions and that all your questions have been answered to your satisfaction, and that you understand the risks and that there are no guarantees that you will receive any benefits from taking part in this study, and that you agree to take part in the study.  You are not giving up any legal rights to which you are entitled by signing this informed consent document though you are providing your",,,yes,yes,"This document tells you what will happen during the study if you choose to take part. Your signature and date indicates that you have read and understood this consent form, this study has been explained to you, you have been given the chance to ask any questions and that all your questions have been answered to your satisfaction, and that you understand the risks and that there are no guarantees that you will receive any benefits from taking part in this study, and that you agree to take part in the study.  You are not giving up any legal rights to which you are entitled by signing this informed consent document though you are providing your
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Acknowledgment and Signatures,authorization as outlined in this informed consent document. You will be given a copy of this consent form to keep for your records.,,,yes,yes,"authorization as outlined in this informed consent document. You will be given a copy of this consent form to keep for your records.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Acknowledgment and Signatures,"Subject Name (Please Print)	Signature of Subject	Date Signed",,Nafisa Ali,yes,yes,"Subject Name (Please Print)	Signature of Subject	Date Signed
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Acknowledgment and Signatures,"Printed Name of Legally	Signature of Legally	Date Signed",,Nafisa Ali,yes,yes,"Printed Name of Legally	Signature of Legally	Date Signed
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Acknowledgment and Signatures,"Authorized Representative (if applicable)	Authorized Representative",,Natasha Ali,yes,yes,"Authorized Representative (if applicable)	Authorized Representative
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Acknowledgment and Signatures,Authority of Legally Authorized Representative to act on behalf of Subject,,Sister,yes,yes,"Authority of Legally Authorized Representative to act on behalf of Subject
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Acknowledgment and Signatures,"*Authority to act on behalf of another includes, but is not limited to parent, guardian, or durable power of attorney for health care.",,,yes,yes,"*Authority to act on behalf of another includes, but is not limited to parent, guardian, or durable power of attorney for health care.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Acknowledgment and Signatures,"Printed Name of Person Explaining Consent Form	Signature of Person Explaining	Date Signed",,Natasha Ali,yes,yes,"Printed Name of Person Explaining Consent Form	Signature of Person Explaining	Date Signed
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Acknowledgment and Signatures,Consent Form (if other than the Investigator),,,yes,yes,"Consent Form (if other than the Investigator)
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Acknowledgment and Signatures,"Printed Name of Investigator	Signature of Investigator	Date Signed",,Kamini U,yes,yes,"Printed Name of Investigator	Signature of Investigator	Date Signed
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
"*If the participant cannot read, hear, or see the signature of an impartial witness is required. Please have impartial witness sign Ã¢ÂÂImpartial Witness for Informed Consent ProcessÃ¢ÂÂ page in the appendix.",,,,yes,yes,"
I agree to the above statement",Certificate,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
"24 hour phone number for subjects to call for questions:	502-562-4370",,,,yes,yes,"
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
"Sponsor assigned number:	CA209-9DW",,,,yes,yes,"
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
"Industry Contracts/Grant number:	183918","Clinicaltrials.gov identifier:		NCT04039607 Sponsor(s) name & address:	Bristol-Myers Squibb Research and Development",,,yes,yes,"Clinicaltrials.gov identifier:		NCT04039607 Sponsor(s) name & address:	Bristol-Myers Squibb Research and Development
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
3401 Princeton Pike,"Lawrenceville, NJ 08648 Investigator name & address:	Vivek Sharma, M.D.",,,yes,yes,"Lawrenceville, NJ 08648 Investigator name & address:	Vivek Sharma, M.D.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Medical Oncology Department 529 S. Jackson St.,"Louisville, KY 40202",,,yes,yes,"Louisville, KY 40202
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
(502)562-4370,"Site(s) where study is to be conducted: University of Louisville, James Graham Brown",,,yes,yes,"Site(s) where study is to be conducted: University of Louisville, James Graham Brown
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Cancer Center and University of Louisville Hospital 529-530 S. Jackson St.,"Louisville, KY 40202",,,yes,yes,"Louisville, KY 40202
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
REVOCATION OF AUTHORIZATION FOR USE AND DISCLOSURE OF YOUR HEALTH INFORMATION FOR RESEARCH,Return To:,,,yes,yes,"Return To:
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
REVOCATION OF AUTHORIZATION FOR USE AND DISCLOSURE OF YOUR HEALTH INFORMATION FOR RESEARCH,OR,,,yes,yes,"OR
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
REVOCATION OF AUTHORIZATION FOR USE AND DISCLOSURE OF YOUR HEALTH INFORMATION FOR RESEARCH,To Whom It May Concern:,,,yes,yes,"To Whom It May Concern:
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
REVOCATION OF AUTHORIZATION FOR USE AND DISCLOSURE OF YOUR HEALTH INFORMATION FOR RESEARCH,I would like to discontinue my participation in the research study noted above. I understand that health information already collected will continue to be used as discussed in the Authorization I signed when joining the study.,,,yes,yes,"I would like to discontinue my participation in the research study noted above. I understand that health information already collected will continue to be used as discussed in the Authorization I signed when joining the study.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
REVOCATION OF AUTHORIZATION FOR USE AND DISCLOSURE OF YOUR HEALTH INFORMATION FOR RESEARCH,Your options are:,,,yes,yes,"Your options are:
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
REVOCATION OF AUTHORIZATION FOR USE AND DISCLOSURE OF YOUR HEALTH INFORMATION FOR RESEARCH,Bullet- Withdraw Permission for use of the data from My Samples in Additional Research,,,yes,yes,"Bullet- Withdraw Permission for use of the data from My Samples in Additional Research
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
REVOCATION OF AUTHORIZATION FOR USE AND DISCLOSURE OF YOUR HEALTH INFORMATION FOR RESEARCH,Bullet- Withdraw from Study & Discontinue Authorization:,,,yes,yes,"Bullet- Withdraw from Study & Discontinue Authorization:
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
REVOCATION OF AUTHORIZATION FOR USE AND DISCLOSURE OF YOUR HEALTH INFORMATION FOR RESEARCH,Discontinue my authorization for the future use and disclosure of protected health information. In,,,yes,yes,"Discontinue my authorization for the future use and disclosure of protected health information. In
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
REVOCATION OF AUTHORIZATION FOR USE AND DISCLOSURE OF YOUR HEALTH INFORMATION FOR RESEARCH,"some instances, the research team may need to use your information even after you discontinue your authorization, for example, to notify you or government agencies of any health or safety concerns that were identified as part of your study participation.",,,yes,yes,"some instances, the research team may need to use your information even after you discontinue your authorization, for example, to notify you or government agencies of any health or safety concerns that were identified as part of your study participation.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
REVOCATION OF AUTHORIZATION FOR USE AND DISCLOSURE OF YOUR HEALTH INFORMATION FOR RESEARCH,"Bullet- Withdraw from Study Treatment, but Continue Authorization:",,,yes,yes,"Bullet- Withdraw from Study Treatment, but Continue Authorization:
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
REVOCATION OF AUTHORIZATION FOR USE AND DISCLOSURE OF YOUR HEALTH INFORMATION FOR RESEARCH,Allow the research team to continue collecting information from me and my personal health,,,yes,yes,"Allow the research team to continue collecting information from me and my personal health
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
REVOCATION OF AUTHORIZATION FOR USE AND DISCLOSURE OF YOUR HEALTH INFORMATION FOR RESEARCH,information. This would be done only as needed to support the goals of the study and would not be used for purposes other than those already described in the research authorization.,,,yes,yes,"information. This would be done only as needed to support the goals of the study and would not be used for purposes other than those already described in the research authorization.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
REVOCATION OF AUTHORIZATION FOR USE AND DISCLOSURE OF YOUR HEALTH INFORMATION FOR RESEARCH,"Printed Name and Signature of Subject	Date Signed",,,yes,yes,"Printed Name and Signature of Subject	Date Signed
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",Yes
REVOCATION OF AUTHORIZATION FOR USE AND DISCLOSURE OF YOUR HEALTH INFORMATION FOR RESEARCH,"Signature of SubjectÃ¢ÂÂs Legal Representative (if subject is unable to sign)	Date Signed",,,yes,yes,"Signature of SubjectÃ¢ÂÂs Legal Representative (if subject is unable to sign)	Date Signed
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",Yes
REVOCATION OF AUTHORIZATION FOR USE AND DISCLOSURE OF YOUR HEALTH INFORMATION FOR RESEARCH,"Printed Name of SubjectÃ¢ÂÂs Legal Representative	Birthdate of Subject",,,yes,yes,"Printed Name of SubjectÃ¢ÂÂs Legal Representative	Birthdate of Subject
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",Yes
REVOCATION OF AUTHORIZATION FOR USE AND DISCLOSURE OF YOUR HEALTH INFORMATION FOR RESEARCH,Relationship of Legal Representative to Subject,,,yes,yes,"Relationship of Legal Representative to Subject
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",Yes
REVOCATION OF AUTHORIZATION FOR USE AND DISCLOSURE OF YOUR HEALTH INFORMATION FOR RESEARCH,"SubjectÃ¢ÂÂs Address	SubjectÃ¢ÂÂs Phone Number",,,yes,yes,"SubjectÃ¢ÂÂs Address	SubjectÃ¢ÂÂs Phone Number
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
REVOCATION OF AUTHORIZATION FOR USE AND DISCLOSURE OF YOUR HEALTH INFORMATION FOR RESEARCH,Optional:,,,yes,yes,"Optional:
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
REVOCATION OF AUTHORIZATION FOR USE AND DISCLOSURE OF YOUR HEALTH INFORMATION FOR RESEARCH,I am ending my participation in this study because:,,,yes,yes,"I am ending my participation in this study because:
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
APPENDIX,Impartial Witness for Informed Consent Process,,,yes,yes,"Impartial Witness for Informed Consent Process
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
IRB#:,PI:,,,yes,yes,"PI:
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Study Title:,Signature of Impartial Witness:,,,yes,yes,"Signature of Impartial Witness:
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Study Title:,"I confirm that the information in the consent form and any other written information was accurately explained to, and apparently understood by, the subject. An opportunity was provided for the subject to ask questions. The subject freely consented to be in the research study.",,,yes,yes,"I confirm that the information in the consent form and any other written information was accurately explained to, and apparently understood by, the subject. An opportunity was provided for the subject to ask questions. The subject freely consented to be in the research study.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",Yes
Study Title:,"Signature of Impartial Witness	Date",,,yes,yes,"Signature of Impartial Witness	Date
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Study Title:,Printed Name of Impartial Witness,,,yes,yes,"Printed Name of Impartial Witness
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",Yes
Study Title:,Subjects Printed Name,,,yes,yes,"Subjects Printed Name
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",
Study Title:,Note to researcher: Attach this signature page to the version of the informed consent that is signed by the Person Explaining Consent and the Principal Investigator. Please also enter the Subjects printed name on the appropriate line of the informed consent.,,,yes,yes,"Note to researcher: Attach this signature page to the version of the informed consent that is signed by the Person Explaining Consent and the Principal Investigator. Please also enter the Subjects printed name on the appropriate line of the informed consent.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",Yes
Study Title:,Impartial Witness: non-involved observer of the consent process for enrollment into a research study.,,,yes,yes,"Impartial Witness: non-involved observer of the consent process for enrollment into a research study.
I agree to the above statement",Study,"{'Drug': 'Nivolumab', 'Disease': 'Hepatocellular Carcinoma', 'country': 'United States'}",Yes
